QUARTERLY REPORT

Q2 2026 — Quarterly report

Q2 2026PDF · 57 pages2.4 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 2026
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-16751
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value ELV New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”,
“smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
As of July 10, 2026, 216,869,290 shares of the Registrant’s Common Stock were outstanding.

-- 1 of 57 --

Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended June 30, 2026
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 . . . . . . . . . . . . . . . 2
Consolidated Statements of Income (Unaudited) for the Three and Six Months Ended June 30, 2026 and
2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Consolidated Statements of Comprehensive Income (Unaudited) for the Three and Six Months Ended
June 30, 2026 and 2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2026 and 2025 . 5
Consolidated Statements of Changes in Total Equity (Unaudited) for the Six Months Ended June 30,
2026 and 2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Notes to Consolidated Financial Statements (Unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK . . . . . . . . . . . . . . . 53
ITEM 4. CONTROLS AND PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
ITEM 1A. RISK FACTORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS . . . . . . . . . . . . . . . . 54
ITEM 3. DEFAULTS UPON SENIOR SECURITIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
ITEM 4. MINE SAFETY DISCLOSURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
ITEM 5. OTHER INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
ITEM 6. EXHIBITS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
-1-

-- 2 of 57 --

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
June 30,
2026 December 31,
2025
(Unaudited)
(In millions, except share and per share data)
Assets
Current assets:
Cash and cash equivalents $ 10,232 $ 9,491
Fixed maturity securities (amortized cost of $25,962 and $25,773; allowance for credit losses of $55 and $21) 25,719 25,884
Equity securities 1,563 740
Premium receivables, net 10,991 10,073
Self-funded receivables, net 5,583 5,162
Other receivables 6,818 6,307
Other current assets 6,278 5,344
Total current assets 67,184 63,001
Long-term investments:
Fixed maturity securities (amortized cost of $1,263 and $1,116; allowance for credit losses of $0 and $0) 1,259 1,121
Other invested assets 11,130 10,839
Property and equipment, net 4,645 4,679
Goodwill 28,339 28,344
Other intangible assets 10,983 11,200
Other noncurrent assets 2,898 2,310
Total assets $ 126,438 $ 121,494
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 18,463 $ 17,084
Other policyholder liabilities 3,463 3,632
Unearned income 1,640 1,493
Accounts payable and accrued expenses 6,632 7,322
Short-term borrowings — 150
Current portion of long-term debt 375 1,099
Other current liabilities 13,681 10,255
Total current liabilities 44,254 41,035
Long-term debt, less current portion 30,669 30,797
Deferred tax liabilities, net 2,206 2,110
Other noncurrent liabilities 4,287 3,526
Total liabilities 81,416 77,468
Commitments and contingencies – Note 10
Shareholders’ equity
Preferred stock, without par value, shares authorized 100,000,000; shares issued and outstanding – none — —
Common stock, par value $0.01, shares authorized 900,000,000; shares issued and outstanding –
216,841,146 and 220,723,898 2 2
Additional paid-in capital 8,917 8,938
Retained earnings 36,675 35,393
Accumulated other comprehensive loss (711) (451)
Total shareholders’ equity 44,883 43,882
Noncontrolling interests 139 144
Total equity 45,022 44,026
Total liabilities and equity $ 126,438 $ 121,494
See accompanying notes.
-2-

-- 3 of 57 --

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited)
Three Months Ended
June 30 Six Months Ended
June 30
2026 2025 2026 2025
(In millions, except per share data)
Revenues
Premiums $ 41,279 $ 41,271 $ 82,303 $ 82,158
Product revenue 6,264 6,042 12,489 11,851
Service fees 2,283 2,108 4,528 4,177
Total operating revenue 49,826 49,421 99,320 98,186
Net investment income 704 486 1,469 1,076
Net losses on financial instruments (56) (131) (134) (595)
Total revenues 50,474 49,776 100,655 98,667
Expenses
Benefit expense 37,024 36,706 72,639 72,018
Cost of products sold 5,492 5,293 10,955 10,276
Operating expense 5,547 4,997 11,877 10,297
Interest expense 364 341 721 685
Amortization of other intangible assets 110 147 222 302
Total expenses 48,537 47,484 96,414 93,578
Income before income tax expense 1,937 2,292 4,241 5,089
Income tax expense 483 548 1,027 1,161
Net income 1,454 1,744 3,214 3,928
Net loss (gain) attributable to noncontrolling interests 9 (1) 13 (2)
Shareholders’ net income $ 1,463 $ 1,743 $ 3,227 $ 3,926
Shareholders’ net income per share
Basic $ 6.74 $ 7.74 $ 14.78 $ 17.39
Diluted $ 6.71 $ 7.72 $ 14.73 $ 17.33
Dividends per share $ 1.72 $ 1.71 $ 3.44 $ 3.42
See accompanying notes.
-3-

-- 4 of 57 --

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
June 30 Six Months Ended
June 30
2026 2025 2026 2025
(In millions)
Net income $ 1,454 $ 1,744 $ 3,214 $ 3,928
Other comprehensive income (loss), net of tax:
Net unrealized investment gains (losses)
Change in gross unrealized investment gains (losses) 31 144 (370) 396
Income tax effect (7) (34) 86 (93)
Total change in unrealized investment gains (losses), net of
tax 24 110 (284) 303
Gross reclassification adjustment for net realized investment
losses included in earnings 1 49 44 105
Income tax effect — (11) (10) (25)
Change in net unrealized investment gains (losses) 25 148 (250) 383
Pension and other benefits
Change during the period 3 3 7 6
Income tax effect (1) (1) (2) (9)
Change in pension and other benefits 2 2 5 (3)
Other
Change during the period 3 2 (17) 12
Income tax effect — — 2 (3)
Change in other 3 2 (15) 9
Other comprehensive income (loss) 30 152 (260) 389
Net loss (gain) attributable to noncontrolling interests 9 (1) 13 (2)
Other comprehensive income attributable to noncontrolling
interests — (1) — (2)
Total shareholders’ comprehensive income $ 1,493 $ 1,894 $ 2,967 $ 4,313
See accompanying notes.
-4-

-- 5 of 57 --

Elevance Health, Inc.
Consolidated Statements of Cash Flows (Unaudited)
Six Months Ended
June 30
2026 2025
(In millions)
Operating activities
Net income $ 3,214 $ 3,928
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments 134 595
Equity in net earnings of other invested assets (567) (138)
Depreciation and amortization 720 753
Deferred income taxes (123) (226)
Impairment of property and equipment 37 —
Share-based compensation 130 162
Changes in operating assets and liabilities:
Receivables, net (1,831) (4,097)
Other invested assets — (35)
Other assets (1,441) (604)
Policy liabilities 1,216 387
Unearned income 147 53
Accounts payable and other liabilities 4,124 1,690
Income taxes 488 603
Other, net (3) —
Net cash provided by operating activities 6,245 3,071
Investing activities
Purchases of investments (7,867) (8,102)
Proceeds from sale of investments 6,070 7,683
Maturities, calls and redemptions from investments 984 748
Changes in securities lending collateral (142) (466)
Purchases of subsidiaries, net of cash acquired 5 54
Purchases of property and equipment (522) (463)
Other, net (11) (38)
Net cash used in investing activities (1,483) (584)
Financing activities
Repayments of long-term borrowings (750) (1,250)
Proceeds from short-term borrowings 825 —
Repayments of short-term borrowings (975) (5)
Changes in securities lending payable 142 466
Changes in bank overdrafts (1,181) 631
Repurchase and retirement of common stock (1,358) (1,258)
Cash dividends (749) (771)
Proceeds from issuance of common stock under employee stock plans 63 21
Taxes paid through withholding of common stock under employee stock plans (35) (40)
Other, net 9 (11)
Net cash used in financing activities (4,009) (2,217)
Effect of foreign exchange rates on cash and cash equivalents (12) 2
Change in cash and cash equivalents 741 272
Cash and cash equivalents at beginning of period 9,491 8,288
Cash and cash equivalents at end of period $ 10,232 $ 8,560
See accompanying notes.
-5-

-- 6 of 57 --

Elevance Health, Inc.
Consolidated Statements of Changes in Total Equity
(Unaudited)
Total Shareholders’ Equity
Common Stock
Additional
Paid-in
Capital Retained
Earnings
Accumulated Other Comprehensive Loss
Noncontrolling
Interests Total
Equity	(In millions) Number of
Shares Par
Value
Net Unrealized
Investment
Gains (Losses) Pension and
Other Benefits Other
December 31, 2025 220.7 $ 2 $ 8,938 $ 35,393 $ 108 $ (332) $ (227) $ 144 $ 44,026
Net income — — — 1,764 — — — (4) 1,760
Other comprehensive income (loss) — — — — (275) 3 (18) — (290)
Repurchase and retirement of common stock,
including excise tax (3.6) — (151) (983) — — — — (1,134)
Dividends and dividend equivalents — — — (378) — — — — (378)
Issuance of common stock under employee
stock plans, net of related tax benefits 0.3 — 58 — — — — — 58
March 31, 2026 217.4 $ 2 $ 8,845 $ 35,796 $ (167) $ (329) $ (245) $ 140 $ 44,042
Net income — — — 1,463 $ — — — (9) $ 1,454
Other comprehensive income — — — — 25 2 3 — 30
Noncontrolling interests adjustment — — — — — — — 8 8
Repurchase and retirement of common stock,
including excise tax (0.8) — (28) (208) — — — — (236)
Dividends and dividend equivalents — — — (376) — — — — (376)
Issuance of common stock under employee
stock plans, net of related tax benefits 0.2 — 100 — — — — — 100
June 30, 2026 216.8 $ 2 $ 8,917 $ 36,675 $ (142) $ (327) $ (242) $ 139 $ 45,022
-6-

-- 7 of 57 --

Elevance Health, Inc.
Consolidated Statements of Changes in Equity (continued)
(Unaudited)
Total Shareholders’ Equity
Common Stock Accumulated Other Comprehensive Loss
Noncontrolling
Interests Total
Equity
Additional
Paid-in
Capital Retained
Earnings
Net Unrealized
Investment
Gains (Losses) Pension and
Other Benefits Other	(In millions) Number of
Shares Par
Value
December 31, 2024 227.5 $ 2 $ 8,911 $ 33,549 $ (523) $ (399) $ (225) $ 111 $ 41,426
Net income — — — 2,183 — — — 1 2,184
Other comprehensive income (loss) — — — — 234 (5) 7 1 237
Noncontrolling interests adjustment — — — — — — — 4 4
Repurchase and retirement of common stock,
including excise tax (2.2) — (97) (799) — — — — (896)
Dividends and dividend equivalents — — — (387) — — — — (387)
Issuance of common stock under employee
stock plans, net of related tax benefits
0.4 — 52 — — — — — 52
March 31, 2025 225.7 $ 2 $ 8,866 $ 34,546 $ (289) $ (404) $ (218) $ 117 $ 42,620
Net income — — — 1,743 — — — 1 1,744
Other comprehensive income — — — — 147 2 2 1 152
Noncontrolling interests adjustment — — — — — — — 10 10
Repurchase and retirement of common stock,
including excise tax (1.0) — (27) (354) — — — — (381)
Dividends and dividend equivalents — — — (386) — — — — (386)
Issuance of common stock under employee
stock plans, net of related tax benefits
0.1 — 92 — — — — — 92
June 30, 2025 224.8 $ 2 $ 8,931 $ 35,549 $ (142) $ (402) $ (216) $ 129 $ 43,851
See accompanying notes.
-7-

-- 8 of 57 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
June 30, 2026
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial
Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise
requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving approximately 44.9 million medical members
through our affiliated health plans as of June 30, 2026. We offer a broad spectrum of network-based managed care risk-based
plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care
services to fee-based customers, including claims processing, stop loss insurance, care provider network access, medical
management, care management, wellness programs, actuarial services and other administrative services. Across these
markets, we generate revenue through risk-based premiums, administrative fees from self-funded employers and pharmacy
and health service fees through our Carelon businesses. We provide services to the federal government in connection with our
Federal Health Products & Services business, which administers the Federal Employee Program® (“FEP®”). We provide an
array of specialty services both to customers of our subsidiary health plans and to unaffiliated health plans, including
pharmacy services, stop loss insurance, dental, vision and supplemental health insurance benefits, as well as integrated health
services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and
Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30
counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate
New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of
these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct
business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members
in numerous states as Wellpoint, Carelon, MMM and/or Simply Healthcare. We are licensed to conduct insurance operations
in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
Our portfolio consists of the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our Anthem-branded and affiliated Blue
Cross and/or Blue Shield licensed Medicare, Medicaid, and commercial Health Benefit plans;
• Wellpoint — represents our Wellpoint branded Medicare, Medicaid and commercial Health Benefit plans and other
non-BCBSA brands; and
• Carelon — represents our healthcare related services and capabilities, including our CarelonRx and Carelon Services
businesses.
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon
Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating
segment, as well as corporate expenses not allocated to our other reportable segments). For additional information on
reportable segments see Note 13, “Segment Information.”
-8-

-- 9 of 57 --

2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance
with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not
include all the information and footnotes required by GAAP for annual financial statements. We have omitted certain
footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended
December 31, 2025 (the “2025 Annual Report on Form 10-K”), unless the information contained in those disclosures
materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring
adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and six months
ended June 30, 2026 and 2025 have been recorded. The results of operations for the three and six months ended June 30,
2026 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2026, or any
other period. The seasonal nature of portions of our healthcare and related benefits business, as well as competitive and other
market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These
unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements
as of and for the year ended December 31, 2025 included in our 2025 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar
(“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during
the period. The net effect of these translation adjustments is included in “Other” in our consolidated statements of
comprehensive income.
Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.
Cash and Cash Equivalents: Cash and cash equivalents includes available cash and all highly liquid investments with
maturities of three months or less when purchased. We control a number of bank accounts that are used exclusively to hold
customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain
regulatory and contractual requirements. These amounts totaled $668 and $348 at June 30, 2026 and December 31, 2025,
respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those
securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we
classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy
contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it
is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we
write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements
of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not
have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment
loss in our consolidated statements of income. The non-credit component of the impairment is recognized in “Accumulated
other comprehensive loss.” Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed
maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in “Accumulated
other comprehensive loss.”
The credit component of an impairment is determined primarily by comparing the net present value of projected future
cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our
best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of
purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the
underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default
rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated
with a default.
-9-

-- 10 of 57 --

For asset-backed securities included in “Fixed maturity securities,” we recognize income using an effective yield based
on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the
effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date
of the securities. Such adjustments are reported within “Net investment income” in our consolidated statements of income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within “Net
losses on financial instruments.” Certain marketable equity securities are held to satisfy contractual obligations and are
reported under the caption “Other invested assets” in our consolidated balance sheets.
We have investments in limited partnerships (“LPs”) and companies in which our ownership interest may enable us to
influence the operating or financial decisions of the investee company, including unconsolidated variable interest entities.
These investments are accounted for using the equity method of accounting and are reported within “Other invested assets” in
our consolidated balance sheets. Our proportionate share of equity in net income (loss) for these LPs and unconsolidated
investee companies is reported within “Net investment income” in our consolidated statements of income. The carrying value
of these investments is written down, or impaired, to fair value when a decline in value is considered to be other-than
temporary. In applying the equity method (including assessment for other-than temporary impairment), we use financial
information provided by the LPs and investee companies, generally on a one-to three-month lag. We consolidate investee
companies in certain other instances where it is deemed to exercise control or is considered the primary beneficiary of a
variable interest entity.
Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of
loss allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at
which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs,
collection of cash and write-offs.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other
members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the
caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are
recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific
securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. Under Financial Accounting Standards Board
(“FASB”) guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we
recognize the collateral as an asset, which is reported in “Other current assets” in our consolidated balance sheets, and we
record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption
“Other current liabilities.” The securities on loan are reported in the applicable investment category in our consolidated
balance sheets. Unrealized gains or losses on securities lending collateral are included in “Accumulated other comprehensive
loss” as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged
can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower
than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the
loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected
accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion
before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the
investments to higher quality and shorter duration instruments.
-10-

-- 11 of 57 --

Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is
based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs.
Premium receivables are reported net of an allowance for doubtful accounts of $187 and $167 at June 30, 2026 and
December 31, 2025, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-
funded receivables are reported net of an allowance for doubtful accounts of $153 and $145 at June 30, 2026 and
December 31, 2025, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due
from brokers on investment trades that have not yet settled, accrued investment income and other miscellaneous amounts due
to us. These receivables are reported net of an allowance for doubtful accounts of $1,737 and $1,509 at June 30, 2026 and
December 31, 2025, respectively. During the quarter ended June 30, 2025, we realized a $209 settlement with a value-based
care provider, which allowed us to release $129 from the allowance for doubtful accounts. Of the settlement amount, $154
pertained to services rendered in 2024.
Revenue Recognition: Premiums for risk-based contracts are recognized as revenue over the period insurance coverage
is provided, and, if applicable, net of amounts recognized for medical loss ratio rebates, risk adjustment, reinsurance and risk
corridor under contractual premium stabilization arrangements, the Affordable Care Act (“ACA”) or other regulatory
requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual
terms. We estimate amounts receivable and payable under these contractual terms, and to the extent that such estimated
amounts vary from the final amounts paid, the adjustments are included in earnings in the period of final settlement. Premium
payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premium
payments related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets
as “Unearned income”. Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on
the estimated loss experience of the contract. Premium rates for certain lines of business are subject to approval by the
Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted
government agencies require that we defer the recognition of any increases to the period in which the premium rates become
final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the
premium rate increase, the membership to which it applies and the length of the delay between the effective date of the rate
increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes
effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the
rate is finalized.
We also record premiums for certain value-based arrangements of our Carelon Services care delivery businesses.
Under these value-based arrangements, we carry financial responsibility across medical claims costs through risk contracts
with health plans in which we deliver, integrate, direct and control certain healthcare services for patients. In exchange, we
receive a premium that is typically paid on a per-patient per-month basis and performance-based payments that are
recognized when performance metrics are achieved. We consider these value-based arrangements to represent a single
performance obligation where revenues are recognized in the period in which healthcare services are made available.
Service fees include revenue from certain group contracts that provide for the group to be at risk for all or, with
supplemental insurance arrangements, a portion, of their claims experience. We charge these fee-based groups an
administrative fee, which is based on the number of members in a group and the group’s claim experience. In addition,
service fees include amounts received for the administration of Medicare, certain other government programs, and
administrative services arrangements of our Carelon subsidiaries. Generally, each fee-based arrangement includes services
which constitute a single suite of services provided and for which consideration is based upon an agreed-upon rate, regardless
of the amount of services provided in a given period. As with premiums, each fee-based arrangement may include terms with
retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable
consideration within the transaction price. As such, each fee-based arrangement contains a single performance obligation that
constitutes a series, and revenue is recognized over time as the services are performed. All benefit payments under these
programs are excluded from benefit expense.
-11-

-- 12 of 57 --

The determination of whether services are distinct performance obligations that should be accounted for separately
or combined as one unit of accounting may require significant judgment. The estimation of variable consideration to be
recognized requires significant judgment in the determination of the level of achievement of performance incentives, service
level achievements subject to performance penalties, and the completion level of tasks subject to implementation fees.
Product revenue represents services performed by CarelonRx for unaffiliated pharmacy customers and includes
ingredient costs (net of any rebates or discounts), including co-payments made by or on behalf of the customer, and service
fees. Unaffiliated pharmacy customers include our fee-based groups that have contracted with CarelonRx for pharmacy
services and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in
consolidation, excluding co-payments and subsidies made by or on behalf of affiliated customers. Product revenue for
pharmacy services is recognized using the gross method at the negotiated contract price when CarelonRx has concluded that
it is the principal, and it controls the services before prescription drugs are transferred to the customer. CarelonRx determines
whether it is the principal based on its contractual rights to design and develop a listing of prescription drugs offered to the
customer (formulary management); its control over establishing the pharmacy network available to the customer to have its
prescription fulfilled (network management); and its discretion over establishing the pricing for prescription drugs. Overall,
control over these activities indicates CarelonRx is primarily responsible for fulfilling the promise to provide pharmacy
services. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it
expects to be entitled to in exchange for the products or services provided.
For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract
costs recorded on our consolidated balance sheets at June 30, 2026 or December 31, 2025. For the three and six months ended
June 30, 2026 and 2025, revenue recognized from performance obligations related to prior periods, such as due to changes in
transaction price, was not material. For contracts that have an original, expected duration of greater than one year, revenue
expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with
variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In July 2025, the FASB issued Accounting Standards Update No. 2025-05,
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract
Assets (“ASU 2025-05”). This standard introduces a practical expedient for all entities when estimating expected credit losses
on current accounts receivable and contract assets arising from transactions under Accounting Standards Codification
(“ASC”) Topic 606. Under the practical expedient, entities may assume that conditions at the balance sheet date remain
unchanged over the life of the asset, reducing the need to prepare complex macroeconomic forecasts for short-term balances.
ASU 2025-05 became effective for our fiscal years beginning after December 15, 2025, and interim periods within such fiscal
years, with prospective application required. We adopted these amendments on January 1, 2026 and applied the amendments
on a prospective basis. The adoption of ASU 2025-05 did not have an impact on our consolidated financial statements and
disclosures.
Recent Accounting Guidance Not Yet Adopted: In November 2024, the FASB issued Accounting Standards Update No.
2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40):
Disaggregation of Income Statement Expenses (“ASU 2024-03”). This standard requires additional expense breakdowns in
the footnotes for items such as inventory purchases, employee compensation, depreciation, and intangible asset amortization.
Public companies must also provide a qualitative description of remaining expense amounts not separately disclosed, as well
as the definition and total amount of selling expenses. ASU 2024-03 is effective for our fiscal year beginning after December
15, 2026, and for interim periods within our fiscal year beginning after December 15, 2027. The amendments are to be
applied either prospectively to financial statements issued for reporting periods after the effective date of the update, or
retrospectively to all prior periods presented in the financial statements. We are currently evaluating the effects the adoption
of ASU 2024-03 will have on our consolidated financial statements and related disclosures.
-12-

-- 13 of 57 --

In September 2025, the FASB issued Accounting Standards Update No. 2025-06, Intangibles—Goodwill and Other—
Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU
2025-06”). This standard modernizes the accounting for internal-use software by removing references to prescriptive
development stages and instead requiring capitalization of costs once (1) management has authorized and committed to
funding the software project, and (2) it is probable the project will be completed and placed in service. Entities must evaluate
whether there is “significant development uncertainty,” such as unresolved novel functionality or substantially revised
performance requirements, before meeting this capitalization threshold. ASU 2025-06 is effective for our fiscal years
beginning after December 15, 2027, and interim periods within such fiscal years, with early adoption permitted. Entities may
adopt the amendments prospectively, retrospectively, or under a modified transition approach. We are currently evaluating
the impact of ASU 2025-06 on our consolidated financial statements and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our
2025 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position,
results of operations, cash flows or disclosures.
3. Operating Model Transformation
In the first quarter of 2026, based on a strategic review of our operations, assets and investments, management
implemented the 2026 - 2027 Operating Model Transformation Program (the “Transformation Program”) to streamline
decision-making, simplify organizational structures, and enhance the use of advanced technologies, including artificial
intelligence, across the enterprise. The Transformation Program includes initiatives to reduce organizational layers, realign
roles and responsibilities, and design workflows to support more efficient, technology-enabled operations. These actions also
include the modernization of certain information technology platforms, targeted workforce reductions and role realignments.
Actions to be taken under the Transformation Program were ongoing as of June 30, 2026. Cash outlays associated with this
program, which primarily relate to the personnel-related costs, are expected to be paid through 2028.
During the six months ended June 30, 2026, we incurred $129 of costs towards the Transformation Program, primarily
for personnel-related charges for the reduction and/or relocation of staff, which included severance and related costs. These
charges were recognized as operating expense in the Corporate & Other segment.
The ending liability balance related to the employee termination costs under the Transformation Program at June 30,
2026 was $114, which included charges of $129 and payments of $15 made during the six months ended June 30, 2026.
-13-

-- 14 of 57 --

4. Investments
Fixed Maturity Securities
A summary of current and long-term fixed maturity securities, available-for-sale, at June 30, 2026 and December 31,
2025 is as follows:
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance
For Credit
Losses Estimated
Fair Value
June 30, 2026
Fixed maturity securities:
United States Government securities $ 1,384 $ 2 $ (29) $ — $ 1,357
Government sponsored securities 52 — — — 52
Foreign government securities 13 — — — 13
States, municipalities and political subdivisions, tax-exempt 3,483 76 (60) (3) 3,496
Corporate securities 13,950 222 (176) (4) 13,992
Residential mortgage-backed securities 3,537 21 (155) (2) 3,401
Commercial mortgage-backed securities 1,861 13 (34) (2) 1,838
Other asset-backed securities 2,945 54 (126) (44) 2,829
Total fixed maturity securities $ 27,225 $ 388 $ (580) $ (55) $ 26,978
December 31, 2025
Fixed maturity securities:
United States Government securities $ 1,512 $ 10 $ (19) $ — $ 1,503
Government sponsored securities 80 2 (1) — 81
Foreign government securities 13 — — — 13
States, municipalities and political subdivisions, tax-exempt 3,701 76 (74) (2) 3,701
Corporate securities 13,498 419 (130) (4) 13,783
Residential mortgage-backed securities 3,203 43 (136) (3) 3,107
Commercial mortgage-backed securities 2,078 28 (31) (2) 2,073
Other asset-backed securities 2,804 53 (103) (10) 2,744
Total fixed maturity securities $ 26,889 $ 631 $ (494) $ (21) $ 27,005
Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.
-14-

-- 15 of 57 --

For fixed maturity securities in an unrealized loss position at June 30, 2026 and December 31, 2025, the following table
summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in
an unrealized loss position:
Less than 12 Months 12 Months or Greater
(Securities are whole amounts) Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss
June 30, 2026
Fixed maturity securities:
United States Government securities 47 $ 883 $ (13) 13 $ 122 $ (16)
Government sponsored securities 12 16 — 11 9 —
Foreign government securities 2 7 — 1 — —
States, municipalities and political
subdivisions, tax-exempt 246 606 (8) 360 586 (52)
Corporate securities 1,565 4,705 (80) 644 1,014 (96)
Residential mortgage-backed securities 362 1,159 (16) 1,151 905 (139)
Commercial mortgage-backed securities 186 810 (10) 154 308 (24)
Other asset-backed securities 306 1,152 (25) 178 382 (101)
Total fixed maturity securities 2,726 $ 9,338 $ (152) 2,512 $ 3,326 $ (428)
December 31, 2025
Fixed maturity securities:
United States Government securities 18 $ 460 $ (3) 17 $ 167 $ (16)
Government sponsored securities 4 — — 16 29 (1)
Foreign government securities 1 3 — 2 1 —
States, municipalities and political
subdivisions, tax-exempt 213 486 (8) 522 848 (66)
Corporate securities 568 1,398 (22) 839 1,397 (108)
Residential mortgage-backed securities 169 282 (4) 1,164 1,012 (132)
Commercial mortgage-backed securities 80 308 (6) 212 479 (25)
Other asset-backed securities 154 657 (28) 174 275 (75)
Total fixed maturity securities 1,207 $ 3,594 $ (71) 2,946 $ 4,208 $ (423)
-15-

-- 16 of 57 --

Unrealized losses on our securities shown in the table above have not been recognized into income because, as of
June 30, 2026, we do not intend to sell these investments and it is likely that we will not be required to sell these investments
prior to their anticipated recovery. The declines in fair values are largely due to elevated interest rates driven by the higher
rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amount of $55 and $21 at June 30, 2026 and December 31, 2025,
respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our
assessment of collectability of principal and interest.
The amortized cost and fair value of fixed maturity securities at June 30, 2026, by contractual maturity, are shown below.
Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay
obligations.
Amortized
Cost Estimated
Fair Value
Due in one year or less $ 277 $ 272
Due after one year through five years 3,590 3,581
Due after five years through ten years 9,209 9,273
Due after ten years 5,806 5,785
Mortgage and other asset-backed securities 8,343 8,067
Total fixed maturity securities $ 27,225 $ 26,978
Equity Securities
A summary of current equity securities at June 30, 2026 and December 31, 2025 is as follows:
Exchange traded funds $ 1,481 $ 650
Common equity securities 35 35
Private equity securities 47 55
Total $ 1,563 $ 740
June 30, 2026 December 31, 2025
Equity securities:
Other Invested Assets
A summary of other invested assets at June 30, 2026 and December 31, 2025 is as follows:
Company-owned life insurance $ 3,043 $ 2,927
Equity method investments and joint ventures 3,112 3,136
Limited partnership investments 3,217 3,033
Other 1,758 1,743
Total $ 11,130 $ 10,839
June 30, 2026 December 31, 2025
Other invested assets:
At June 30, 2026, “Other invested assets” included non-controlled equity method investments and joint ventures,
including our minority interest ownership of approximately 40% of Augusta Topco Holdings, L.P. (“Mosaic Health”) and our
40% minority interest ownership of Project Freedom Holdings, LLC, which is the ultimate parent of LIBERTY Dental Plan
Corporation (“Liberty Dental”). See Note 5, “Investments” to our audited consolidated financial statements as of and for the
year ended December 31, 2025 included in Part II, Item 8 of our 2025 Annual Report on Form 10-K.
-16-

-- 17 of 57 --

In connection with our equity method investment in Mosaic Health, we entered into a financing agreement to provide a
term loan of $200 and a line of credit up to $500 to Mosaic Health. Mosaic Health borrowed $100 on the line of credit in
December 2025, which remained outstanding at June 30, 2026. Net amounts receivable under these arrangements were $282
at both June 30, 2026 and December 31, 2025, which are included under the caption “Other invested assets” in our
consolidated balance sheets as of June 30, 2026 and December 31, 2025. Interest income recognized from the financing
arrangement during the three and six months ended June 30, 2026 and 2025 was not material. In addition to the term loan and
line of credit, we committed to providing $70 of additional funding with no additional equity interest in Mosaic Health to
meet any shortfall in operating cash flow and regulatory capital requirements of certain businesses that were contributed by
us to Mosaic Health through December 31, 2026. Additional funding of $34 was provided during the six months ended
June 30, 2026. No additional funding was provided as of December 31, 2025. We also committed to fund any shortfalls
above $70 in those businesses if necessary for which we would receive additional equity interests in Mosaic Health, in which
none has been contributed. Related party transactions with Mosaic Health included care delivery and enablement services
provided in the normal course of business which amounts were included in “Benefit expense” in our consolidated statements
of income amounting to $193 and $386 for the three and six months ended June 30, 2026, respectively, and $171 and $346,
respectively, for the three and six months ended June 30, 2025.
In connection with our equity method investment in Liberty Dental, in December 2024 we entered into a commitment to
provide funding in the form of mandatorily redeemable preferred equity shares in Liberty Dental of up to $250, of which
$165 was disbursed as of both June 30, 2026 and December 31, 2025. Mandatorily redeemable preferred equity in Liberty
Dental of $162 and $137 is included in the caption “Other invested assets” in our consolidated balance sheets at June 30,
2026 and December 31, 2025, respectively. Dividend income recognized from the financing arrangement during the three and
six months ended June 30, 2026 and 2025 was not material. During the three and six months ended June 30, 2026, in the
normal course of business, related party transactions with Liberty Dental included administrative services to our Medicare
Advantage members under a capitated arrangement amounting to $123 and $256, respectively, and $146 and $292,
respectively, for the three and six months ended June 30, 2025 which amounts were included in “Benefit expense” in our
consolidated statements of income.
Investment Gains (Losses)
Net investment gains (losses) for the three and six months ended June 30, 2026 and 2025 are as follows:
Three Months Ended
June 30, Six Months Ended
June 30
2026 2025 2026 2025
Net gains (losses):
Fixed maturity securities:
Gross realized gains from sales $ 30 $ 22 $ 63 $ 49
Gross realized losses from sales (31) (62) (70) (144)
Impairment losses recognized in income — (9) (37) (10)
Net realized losses from sales of fixed maturity securities (1) (49) (44) (105)
Equity securities:
Unrealized gains recognized on equity securities still
held at the end of the period — — (2) (6)
Net realized losses recognized on equity securities sold
during the period — (1) (1) (2)
Net losses on equity securities — (1) (3) (8)
Other investments:
Gross gains 26 8 34 13
Gross losses (1) (6) (6) (99)
Other realized losses recognized in income (60) (83) (96) (394)
Net losses on other investments (35) (81) (68) (480)
Net losses on investments $ (36) $ (131) $ (115) $ (593)
-17-

-- 18 of 57 --

A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to
underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market
conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and
losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited
to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to
reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
During the three and six months ended June 30, 2026, we received total proceeds from sales, maturities, calls or
redemptions of fixed maturity securities of $2,854 and $5,796, respectively. During the three and six months ended June 30,
2025, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,682 and
$6,021, respectively.
Accrued Investment Income
At June 30, 2026 and December 31, 2025, accrued investment income totaled $322 and $295, respectively. We recognize
accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
The fair value of the cash and securities received as collateral for securities loaned at June 30, 2026 and December 31,
2025 was $2,833 and $2,691, respectively. The collateral received was 102% of the market value of the loaned securities at
each of June 30, 2026 and December 31, 2025.
We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and
we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other
current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance
sheets.
At June 30, 2026 and December 31, 2025, the remaining contractual maturities of our securities lending transactions
included overnight and continuous transactions of cash for $2,171 and $2,136, respectively, United States Government
securities for $658 and $552, respectively, and residential mortgage-backed securities for $4 and $3, respectively.
5. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, collars, swaptions, embedded derivatives and warrants. We also enter into master netting
agreements, which reduce credit risk by permitting net settlement of transactions. We posted collateral of $80 and received
collateral of $34 related to our derivative financial instruments at June 30, 2026 and December 31, 2025, respectively.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-
term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the
Secured Overnight Financing Rate (“SOFR”). These derivatives are recorded at fair value and are included in the captions
“Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our
consolidated balance sheets, as applicable.
The unrecognized loss, net of tax, for all expired and terminated interest rate cash flow hedges included in “Accumulated
other comprehensive loss” in our consolidated balance sheets was $187 and $192 as of June 30, 2026 and December 31,
2025, respectively.
During both the three and six months ended June 30, 2026, we recognized net losses of $20 on non-hedging derivatives
included in “Net losses on financial instruments” in our consolidated income statements. During the three and six months
ended June 30, 2025, we recognized net gains of $0 and net losses of $2, respectively, on non-hedging derivatives included in
“Net losses on financial instruments” in our consolidated income statement.
-18-

-- 19 of 57 --

In connection with our equity investment in Mosaic Health (see Note 4, “Investments”), we entered into a limited
partnership and related agreements with the majority owners that provide for certain rights and obligations of each party,
including certain put, call, and purchase price true-up options. These options, if exercised, will result in our purchase of the
units held by the majority owners as early as 2028 but no later than 2030 at a price based on certain multiples of revenue and
earnings of Mosaic Health businesses, subject to various adjustments and qualifications. At inception, we calculated the fair
value of the net put option, which is a Level III measurement (see Note 6, “Fair Value”), using a Monte Carlo simulation,
which relies on assumptions including cash flow projections, risk-free rates, volatility and details specific to the options.
Significant changes in assumptions could result in significantly lower or higher fair value measurements. The carrying value
of the net put option of $1,330, which is a non-cash item originally measured at fair value, is included under the caption
“Other noncurrent liabilities” in our consolidated balance sheets as of June 30, 2026. We have elected to not mark the net put
option to market, as it is an option on large blocks of equity securities, and the carrying value of the net put option will
remain on the consolidated balance sheets until it is exercised, expires, or the terms are substantially amended.
In connection with our equity investment in Liberty Dental (see Note 4, “Investments”), we entered into an agreement
with the majority owners that provides for certain rights and obligations of each party, including certain put and call options.
These options, if exercised, will result in our purchase of the units held by the majority owners as early as the third quarter of
2026, but no later than fourth quarter of 2027 at a price based on certain multiples of earnings of Liberty Dental, subject to
various adjustments and qualifications. We have calculated the fair value of the net put option, which is a Level III
measurement (see Note 6, “Fair Value”), based on assumptions including cash flow projections, risk-free rates, volatility and
details specific to the options. Significant changes in assumptions could result in significantly lower or higher fair value
measurements. The carrying value of the net put option of $396, which is a non-cash item originally measured at fair value, is
included under the caption “Other noncurrent liabilities” in our consolidated balance sheets as of June 30, 2026. We have
elected to not mark the net put option to market, as it is an option on large blocks of equity securities, and the carrying value
of the net put option will remain on the consolidated balance sheets until it is exercised, expires, or the terms are substantially
amended.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,”
included in this Quarterly Report on Form 10-Q.
6. Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of
judgment associated with the inputs used to measure their fair value. These assets and liabilities are classified into one of
three levels of hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate and determine the fair value hierarchy
classification for each class of financial instruments, see Note 7, “Fair Value,” to our audited consolidated financial
statements as of and for the year ended December 31, 2025 included in Part II, Item 8 of our 2025 Annual Report on Form
10-K.
-19-

-- 20 of 57 --

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at
June 30, 2026 and December 31, 2025 is as follows:
Level I Level II Level III Total
June 30, 2026
Assets:
Cash equivalents $ 5,305 $ — $ — $ 5,305
Fixed maturity securities, available-for-sale:
United States Government securities — 1,357 — 1,357
Government sponsored securities — 52 — 52
Foreign government securities — 13 — 13
States, municipalities and political subdivisions, tax-exempt — 3,496 — 3,496
Corporate securities — 13,575 417 13,992
Residential mortgage-backed securities — 3,398 3 3,401
Commercial mortgage-backed securities — 1,838 — 1,838
Other asset-backed securities — 1,961 868 2,829
Total fixed maturity securities, available-for-sale — 25,690 1,288 26,978
Equity securities:
Exchange traded funds 1,481 — — 1,481
Common equity securities — 35 — 35
Private equity securities — — 47 47
Total equity securities 1,481 35 47 1,563
Other invested assets - common equity securities 4 — — 4
Securities lending collateral — 2,833 — 2,833
Derivatives - other assets — 5 — 5
Total assets $ 6,790 $ 28,563 $ 1,335 $ 36,688
Percentage of total assets at fair value 18 % 78 % 4 % 100 %
Liabilities:
Derivatives - other liabilities $ — $ (102) $ — $ (102)
Total liabilities $ — $ (102) $ — $ (102)
December 31, 2025
Assets:
Cash equivalents $ 5,184 $ — $ — $ 5,184
Fixed maturity securities, available-for-sale:
United States Government securities — 1,503 — 1,503
Government sponsored securities — 81 — 81
Foreign government securities — 13 — 13
States, municipalities and political subdivisions, tax-exempt — 3,701 — 3,701
Corporate securities — 13,373 410 13,783
Residential mortgage-backed securities — 3,090 17 3,107
Commercial mortgage-backed securities — 2,073 — 2,073
Other asset-backed securities — 1,878 866 2,744
Total fixed maturity securities, available-for-sale — 25,712 1,293 27,005
Equity securities:
Exchange traded funds 650 — — 650
Common equity securities — 35 — 35
Private equity securities — — 55 55
Total equity securities 650 35 55 740
Other invested assets - common equity securities 6 — — 6
Securities lending collateral — 2,692 — 2,692
Derivatives - other assets — 62 — 62
Total assets $ 5,840 $ 28,501 $ 1,348 $ 35,689
Percentage of total assets at fair value 16 % 80 % 4 % 100 %
Liabilities:
Derivatives - other liabilities $ — $ (28) $ — $ (28)
Total liabilities $ — $ (28) $ — $ (28)
-20-

-- 21 of 57 --

There were no individually material transfers into or out of Level III during the three and six months ended June 30,
2026 or 2025. There were no adjustments to quoted market prices obtained from the pricing services during the three and six
months ended June 30, 2026 or 2025.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured
at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. The fair values of
goodwill and other intangible assets acquired in certain business acquisitions during the years ended December 31, 2025 and
2024 were finalized based on a valuation performed using the income approach. The income approach estimates fair value
based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal
estimates for the expected cash flows and discount rate in the present value calculation.
As discussed in more detail within Note 4, “Investments”, we entered into agreements that included certain put and call
options associated with our minority interest ownership of Mosaic Health in 2024 and Liberty Dental in 2023 (as amended in
2025). The resulting net put option liabilities were recorded at their fair values measured at the dates of acquisition using
Level III inputs with an election not to mark the derivative to market, which is further discussed and disclosed in Note 5,
“Derivative Financial Instruments”. The net put option fair value for Mosaic Health was $2,736 and $2,717 at June 30, 2026
and December 31, 2025, respectively. The net put option fair value for Liberty Dental was $352 and $327 at June 30, 2026
and December 31, 2025, respectively.
Other than the goodwill and intangible assets acquired and liabilities assumed in our business acquisitions and the net put
options on Mosaic Health and Liberty Dental, there were no material assets or liabilities measured at fair value on a
nonrecurring basis during the three and six months ended June 30, 2026 or 2025.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB
guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to
estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets
and certain financial instruments, such as limited partnerships, joint ventures, other non-controlled corporations, corporate-
owned life insurance policies, and policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value
amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables,
other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate
fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
See Note 7, “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31,
2025 included in Part II, Item 8 of our 2025 Annual Report on Form 10-K for details on the methods and assumptions used to
estimate the fair value for each class of financial instruments that are recorded at their carrying value in our consolidated
balance sheets.
-21-

-- 22 of 57 --

A summary of the estimated fair values by level for each class of financial instruments that is recorded at its carrying
value on our consolidated balance sheets at June 30, 2026 and December 31, 2025 is as follows:
Carrying
Value
Estimated Fair Value
Level I Level II Level III Total
June 30, 2026
Assets:
Other invested assets $ 809 $ — $ — $ 787 $ 787
Liabilities:
Debt:
Notes 31,044 — 29,068 — 29,068
Options 1,726 — — 3,088 3,088
December 31, 2025
Assets:
Other invested assets $ 781 $ — $ — $ 762 $ 762
Liabilities:
Debt:
Short-term borrowings 150 — 150 — 150
Notes 31,896 — 30,207 — 30,207
Options 1,726 — — 3,044 3,044
7. Income Taxes
During the three months ended June 30, 2026 and 2025, we recognized income tax expense of $483 and $548,
respectively, which represent effective income tax rates of 24.9% and 23.9%, respectively. During the six months ended June
30, 2026 and 2025, we recognized income tax expense of $1,027 and $1,161, respectively, which represent effective income
tax rates of 24.2% and 22.8%, respectively. The increases in our effective income tax rate compared to the three and six
months ended June 30, 2025 were primarily due to a current year net increase in reserves for uncertain tax positions.
Income taxes netted to a payable of $52 at June 30, 2026 and a receivable of $436 at December 31, 2025. We recognized
income taxes receivable of $224 and $587 as an asset under the caption “Other current assets” and income taxes payable of
$276 and $151 as a liability under the caption “Other current liabilities” in our consolidated balance sheets as of June 30,
2026 and December 31, 2025, respectively.
-22-

-- 23 of 57 --

8. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the six months ended June 30,
2026 and 2025 is as follows:
2026 2025
Gross medical claims payable, beginning of period $ 16,829 $ 15,580
Ceded medical claims payable, beginning of period (48) (13)
Net medical claims payable, beginning of period 16,781 15,567
Business combinations and purchase adjustments — 182
Net incurred medical claims:
Current period 71,743 71,090
Prior periods redundancies (1,195) (1,065)
Total net incurred medical claims 70,548 70,025
Net payments attributable to:
Current period medical claims 56,610 57,117
Prior periods medical claims 12,619 11,802
Total net payments 69,229 68,919
Net medical claims payable, end of period 18,100 16,855
Ceded medical claims payable, end of period 44 16
Gross medical claims payable, end of period $ 18,144 $ 16,871
At June 30, 2026, the total of net incurred but not reported liabilities plus expected development on reported claims was
$15,133, $2,419 and $548 for the claim years 2026, 2025, and 2024 and prior, respectively.
The favorable development recognized in the six months ended June 30, 2026 resulted from both favorable trend and
completion factor development from 2025.
The favorable development recognized in the six months ended June 30, 2025 resulted from trend factors in late 2024
developing more favorably than originally expected as well as a smaller contribution from faster than expected development
of completion factors from the latter part of 2024.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income
for the six months ended June 30, 2026 and 2025 is as follows:
2026 2025
Net incurred medical claims with medical claims payable $ 70,242 $ 67,917
Performance-based risk arrangements without medical claims payable 306 2,108
Total net incurred medical claims 70,548 70,025
Quality improvement and other claims expense 2,091 1,993
Benefit expense $ 72,639 $ 72,018
Net incurred medical claims under certain performance-based risk arrangements that include gain or loss sharing
components do not require a medical claim payable liability.
-23-

-- 24 of 57 --

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for
medical claims payable included in the consolidated balance sheets, as of June 30, 2026 is as follows:
Total
Net medical claims payable, end of period $ 18,100
Ceded medical claims payable, end of period 44
Insurance lines other than short duration 319
Gross medical claims payable, end of period $ 18,463
9. Debt
Long-term debt
The carrying value of our long-term debt at June 30, 2026 and December 31, 2025 consists of the following:
June 30, 2026 December 31, 2025
Senior unsecured notes $ 31,019 $ 31,871
Unsecured surplus note 25 25
Total long-term debt 31,044 31,896
Current portion of long-term debt (375) (1,099)
Long-term debt, less current portion $ 30,669 $ 30,797
On March 15, 2026, we repaid, at maturity, the $750 outstanding balance of our 1.500% senior unsecured notes. During
the twelve months ended December 31, 2025, the Company repaid at maturity $1,250 of its 2.375% senior unsecured notes
and redeemed $400 of its 5.350% senior unsecured notes and $500 of its 4.900% senior unsecured notes.
Short-term borrowings
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides credit of $5,000 and matures in September 2030. In addition, we have an authorized commercial
paper program of up to $5,000, the proceeds of which may be used for general corporate purposes. We also maintain
borrowing arrangements with the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the
Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”), under
which we may obtain advances.
The following table summarizes our outstanding short-term borrowings and advances as of June 30, 2026 and
December 31, 2025.
Facility June 30, 2026 December 31, 2025
Senior revolving credit facility $ — $ —
Commercial paper program $ — $ —
FHLB advances $ — $ 150
All debt is a direct obligation of Elevance Health, Inc., except for the unsecured surplus note and the FHLB advances,
which are obligations of certain subsidiaries. We were in compliance with our debt covenants as of June 30, 2026. For more
information on our short-term borrowings, debt covenants and long-term debt, see Note 13, “Debt,” to our audited
consolidated financial statements as of and for the year ended December 31, 2025 included in Part II, Item 8 of our 2025
Annual Report on Form 10-K.
-24-

-- 25 of 57 --

10. Commitments and Contingencies
Litigation and Regulatory Proceedings
We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a
plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages
being sought, we have noted those alleged damages in the descriptions below.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated
financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In
addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already accrued with
respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible
or probable loss or range of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to
some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii)
there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv)
there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved,
and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings.
With respect to the cases described below, we contest the liability and/or the amount of damages in each matter, and we
believe we have meritorious defenses. We do not believe the outcome of any known pending or threatened legal actions or
proceedings will, in the aggregate, have a material impact on our financial position. However, unanticipated outcomes do
sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our
consolidated financial position or results of operations.
In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the
character incidental to our business and are from time to time involved as a party in various governmental investigations,
audits, reviews and administrative proceedings (“government actions”). These government actions include routine and special
inquiries by and disclosures to state insurance departments, state attorneys general, U.S. Regulatory Agencies, the U.S.
Attorney General and subcommittees of the U.S. Congress. Such government actions could result in the imposition of civil or
criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any
liability that may result from any one of these government actions individually, or in the aggregate, could have a material
adverse effect on our consolidated financial position or results of operations.
Blue Cross Blue Shield Antitrust Litigation
We have been a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or
Blue Shield licensees (the “Blue plans”) across the country. These cases were consolidated into a single, multi-district
proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation (the “BCBSA Litigation”) that is pending in the U.S.
District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue
plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the
percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National
Accounts programs and other arrangements in violation of the Sherman Antitrust Act and related state laws. The cases were
brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
The BCBSA and Blue plans approved and entered into a settlement agreement and release with the subscriber plaintiffs
(the “Subscriber Settlement Agreement”) and a separate settlement agreement and release with the provider plaintiffs (the
“Provider Settlement Agreement”) which settlement received final approval from the Court in September 2022 and August
2025, respectively.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed
and remain pending. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D.
Ala.) (“Alaska Air”); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) (“Jet Blue”);
Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.)
(dismissed without prejudice in June 2023); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.)
and Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 1:21-cv-23448 (S.D. Fla.). Beginning in 2021, Prime
-25-

-- 26 of 57 --

Healthcare Services, Inc., Prime Healthcare Foundation, Inc., Prime Healthcare Management, Inc.and VHS Liquidating Trust
(“VHS”) filed an antitrust action, VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal Super.)
against BCBSA and all Blue plans in California Superior Court bringing similar claims as the BCBSA Litigation. In February
2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue.
In September 2023, the California court presiding over the VHS case upheld its prior order granting in part defendants’
motion to strike based on the statute of limitations. In February 2025, the VHS plaintiffs amended their complaint to add an
additional plaintiff, Children’s Hospital of Los Angeles. Trial for this case is scheduled for March 2027. We intend to
continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome
cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Provider Settlement Agreement have been filed and
have been centralized in the BCBSA Litigation multi-district proceeding. We intend to continue to vigorously defend these
provider follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently
determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S.
District Court for the Southern District of New York (the “District Court”) in a case captioned United States v. Anthem, Inc.
The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the
Centers for Medicare & Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly
failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS
to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified
amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July
2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to
transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain
allegations in the amended complaint, all of which the District Court denied in October 2022. In November 2022, we filed an
answer. In March 2023, discovery commenced. Fact and expert discovery are ongoing with current completion deadlines of
August 31, 2026 and May 10, 2027, respectively. We intend to continue to vigorously defend this suit, which we believe is
without merit; however, the ultimate outcome cannot be presently determined.
CMS Notice
In connection with the notice that the Company received in February 2026 from the Centers for Medicare & Medicaid
Services (“CMS”) regarding certain Medicare Advantage risk adjustment data submission requirements related to diagnosis
codes for dates of service 2015 through April 2023, CMS provided a series of steps required to be completed by July 31,
2026 in order to avoid sanctions being imposed on the Company. On July 13, 2026, the Company received a letter from CMS
stating that the Company has completed all required steps, sanctions will not be imposed and the enforcement process for this
matter has been closed.
As previously disclosed, the Company recorded an accrual in connection with the CMS Notice of approximately $935 at
March 31, 2026 representing its current best estimate of the identified potential exposure for the resubmission of certain
Medicare Advantage risk adjustment data pursuant to applicable loss contingency accounting guidance. On May 27, 2026 we
paid CMS $342, leaving an accrual balance of $593 as of June 30, 2026. The $593 accrual was recorded in “Other current
liabilities” on the consolidated balance sheet as of June 30, 2026 and the $935 in “Operating expense” on the consolidated
statement of income for the six months ended June 30, 2026.
The Company believes that it is reasonably possible that the loss contingency liability for the risk adjustment data
previously disclosed to CMS could differ from the amount originally accrued. Management currently estimates that the
aggregate amount of such liability could range from approximately $320 less than the amount originally accrued up to $320
in excess of the amount originally accrued.
-26-

-- 27 of 57 --

Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve
claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”)
and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred
Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees
arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results
in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability
under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage
claims.
Contractual Obligations and Commitments
In September 2024, we extended our agreement with a vendor for information technology infrastructure and related
management and support services through June 2029. Our remaining commitment under this agreement is approximately
$1,412. We have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination
fees.
CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the country, as well
as to customers outside of the health plans we own. The comprehensive pharmacy services portfolio includes all core
pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy
networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain core
pharmacy services to CaremarkPCS Health, L.L.C. (“CVS”), which is a subsidiary of CVS Health Corporation, pursuant to
an agreement (“CVS Agreement”), with the current contractual term extending through December 31, 2027. We can elect to
have CVS continue to provide services to us for a three-year extension period on the same terms and conditions as in the
current CVS Agreement in the event of a termination or non-renewal by either party.
We have financial guarantees related to standby letters of credit and surety bonds related to certain contractual
commitments, which totaled $783 as of June 30, 2026. We do not believe such obligations will materially affect our financial
position, results of operations, or cash flows.
We have unfunded loan commitments to certain equity investees of $401 at June 30, 2026. We do not believe such
obligations will materially affect our financial position, results of operations, or cash flows.
Vulnerability Concentrations
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents,
investment securities, premium receivables and instruments held through hedging activities. All investment securities are
managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the
amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk
with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base
in the states in which we conduct business. As of June 30, 2026, there were no significant concentrations of financial
instruments in a single investee, industry or geographic location.
-27-

-- 28 of 57 --

11. Capital Stock
Stock Incentive Plans
A summary of stock option activity for the six months ended June 30, 2026 is as follows:
Number of
Shares
Weighted-
Average
Option Price
per Share
Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2026 3.1 $ 373.90
Granted 0.9 295.96
Exercised (0.2) 207.29
Forfeited or expired (0.1) 380.26
Outstanding at June 30, 2026 3.7 $ 361.36 6.25 $ 204
Exercisable at June 30, 2026 2.3 $ 372.60 4.62 $ 123
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for
the six months ended June 30, 2026 is as follows:
Restricted
Stock Shares
and Units
Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2026 1.1 $ 437.32
Granted 0.9 297.62
Vested (0.3) 453.08
Forfeited (0.1) 399.66
Nonvested at June 30, 2026 1.6 $ 355.60
During the six months ended June 30, 2026, we granted approximately 0.3 restricted stock units that are contingent upon
us achieving an earnings target for 2026 and certain qualitative plan metrics over the three-year period from 2026 to 2028.
These grants have been included in the activity shown above but will be subject to adjustment at the end of 2028 based on
results during the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed
discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated
financial statements as of and for the year ended December 31, 2025 included in Part II, Item 8 of our 2025 Annual Report on
Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the six
months ended June 30, 2026 and 2025:
Six Months Ended June 30
2026 2025
Risk-free interest rate 3.97 % 4.29 %
Volatility factor 31.00 % 30.00 %
Quarterly dividend yield 0.585 % 0.432 %
Weighted-average expected life (years) 4.55 4.45
-28-

-- 29 of 57 --

The following weighted-average fair values per option or share were determined for the six months ended June 30, 2026
and 2025:
Six Months Ended June 30
2026 2025
Options granted during the period $ 76.04 $ 107.38
Restricted stock awards granted during the period 297.62 395.28
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the six months ended June 30, 2026 and 2025 is as follows:
Declaration Date Record Date Payment Date
Cash
Dividend
per Share Total
Six Months Ended June 30, 2026
January 27, 2026 March 10, 2026 March 25, 2026 $1.72 $ 376
April 21, 2026 June 10, 2026 June 25, 2026 $1.72 $ 373
Six Months Ended June 30, 2025
January 22, 2025 March 10, 2025 March 25, 2025 $1.71 $ 386
April 16, 2025 June 10, 2025 June 25, 2025 $1.71 $ 385
On July 14, 2026, our Audit Committee declared a third quarter 2026 dividend to shareholders of $1.72 per share,
payable on September 25, 2026 to shareholders of record at the close of business on September 10, 2026.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On October 15, 2024,
our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized an $8,000 increase to the
common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve
the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices,
subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open
market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to
comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is
discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe
it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to
additional paid-in capital and retained earnings.
A summary of common stock repurchases for the six months ended June 30, 2026 and 2025 is as follows:
Six Months Ended June 30
2026 2025
Shares repurchased 4.4 3.2
Average price per share $ 310.89 $ 399.97
Aggregate cost $ 1,358 $ 1,259
Authorization remaining at the end of the period $ 5,337 $ 8,041
We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry
conditions. For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included
in this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the
year ended December 31, 2025 included in Part II, Item 8 of our 2025 Annual Report on Form 10-K.
-29-

-- 30 of 57 --

12. Shareholders' Earnings per Share
The denominator for basic and diluted shareholders' earnings per share for the three and six months ended June 30, 2026
and 2025 is as follows:
Three Months Ended
June 30 Six Months Ended
June 30
2026 2025 2026 2025
Denominator for basic shareholders' earnings per share – weighted-
average shares 217.0 225.2 218.4 225.8
Effect of dilutive securities – employee stock options and non-vested
restricted stock awards
0.9 0.6 0.7 0.7
Denominator for diluted shareholders' earnings per share 217.9 225.8 219.1 226.5
During the three months ended June 30, 2026 and 2025, weighted-average shares related to certain stock options of 1.8
and 1.9, respectively, were excluded from the denominator for diluted shareholders' earnings per share because the stock
options were anti-dilutive. During the six months ended June 30, 2026 and 2025, weighted-average shares related to certain
stock options of 1.8 and 1.7, respectively, were excluded from the denominator for diluted shareholders' earnings per share
because the stock options were anti-dilutive.
We have issued approximately 0.8 cumulative restricted stock units under our stock incentive plans, of which vesting is
contingent upon us meeting specified earnings and qualitative plan performance targets. Contingent restricted stock units are
excluded from the denominator for diluted shareholders’ earnings per share and are included only if and when the
contingency is met. These contingent restricted stock units are being measured over a three-year period and generally vest in
March of the year following each measurement period.
13. Segment Information
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon
Services and Corporate & Other. An immaterial amount of our total consolidated revenues is derived from activities outside
of the U.S. and Puerto Rico.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer
Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEP® members. The Health Benefits
segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-
based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental,
vision and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to
our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a
comprehensive pharmacy services portfolio, which includes all core pharmacy services, such as home delivery and specialty
pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug
database and member services, as well as infusion services and injectable therapies.
Our Carelon Services segment integrates physical, behavioral, and social services with the aim of delivering whole
health affordably by offering a broad array of healthcare related services and capabilities to internal and external customers
through our Carelon Health and Carelon Insights businesses. Carelon promotes affordability by managing complex areas of
the healthcare system, leveraging data and insights to ensure members receive safe, appropriate, high-quality care and
providers are reimbursed accurately and timely. Our approach to cost management relies on capabilities including provider
enablement, value-based networks, member engagement, and utilization management. Our care delivery services primarily
target serving chronic and complex populations by providing personalized care in the home and virtually.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an
operating segment, as well as corporate expenses not allocated to our other reportable segments.
-30-

-- 31 of 57 --

We define operating revenues to include premiums, product revenue and service fees. Operating revenues are derived
from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and
services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating
expense.
Affiliated operating revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and
Carelon Services, in addition to certain administrative and other services provided by our international businesses, which are
recorded at cost or management’s estimate of fair market value. These affiliated operating revenues are eliminated in our
consolidated financial statements.
The accounting policies of the segments are consistent with those described in the summary of significant accounting
policies in Note 2, “Basis of Presentation and Significant Accounting Policies,” except that all capitation risk arrangements
are reported on a gross basis with an adjustment included in eliminations for capitated risk arrangements that are presented on
a net basis under GAAP.
Our chief operating decision maker (the “CODM”) is our Chief Executive Officer. The CODM assesses the performance
of our reportable segments based on operating gain or loss as defined above. The CODM evaluates net investment income,
net gains (losses) on financial instruments, interest expense, depreciation and amortization expense, income taxes and assets,
liabilities and equity on a consolidated basis, as these items are managed in a corporate shared service environment and are
not the responsibility of segment operating management.
The CODM uses operating gain or loss, developed during the annual budget process, and updated during the periodic
forecasting process, as a basis to assess performance and allocate operating and capital resources to each segment.
-31-

-- 32 of 57 --

Financial data by reportable segment for the three and six months ended June 30, 2026 and 2025 is as follows:
Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Three Months Ended June 30, 2026
Premiums $ 40,647 $ — $ 833 $ 833 $ — $ (201) $ 41,279
Product revenue — 6,264 — 6,264 — — 6,264
Service fees 2,073 3 207 210 — — 2,283
Operating revenue -
unaffiliated 42,720 6,267 1,040 7,307 — (201) 49,826
Operating revenue - affiliated — 4,983 6,935 11,918 6 (11,924) —
Operating revenue - total $ 42,720 $ 11,250 $ 7,975 $ 19,225 $ 6 $ (12,125) $ 49,826
Benefit expense $ 36,739 $ — $ 6,743 $ 6,743 $ 6 $ (6,464) $ 37,024
Cost of products sold — 10,473 — 10,473 — (4,981) 5,492
Operating expense 5,085 195 866 1,061 81 (680) 5,547
Operating gain (loss) $ 896 $ 582 $ 366 $ 948 $ (81) $ — $ 1,763
Three Months Ended June 30, 2025
Premiums $ 39,710 $ — $ 1,863 $ 1,863 $ — $ (302) $ 41,271
Product revenue — 6,042 — 6,042 — — 6,042
Service fees 1,872 4 232 236 — — 2,108
Operating revenue -
unaffiliated 41,582 6,046 2,095 8,141 — (302) 49,421
Operating revenue - affiliated — 4,597 5,346 9,943 232 (10,175) —
Operating revenue - total $ 41,582 $ 10,643 $ 7,441 $ 18,084 $ 232 $ (10,477) $ 49,421
Benefit expense $ 35,487 $ — $ 6,290 $ 6,290 $ 8 $ (5,079) $ 36,706
Cost of products sold — 9,884 — 9,884 — (4,591) 5,293
Operating expense 4,535 223 751 974 295 (807) 4,997
Operating gain (loss) $ 1,560 $ 536 $ 400 $ 936 $ (71) $ — $ 2,425
-32-

-- 33 of 57 --

Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Six Months Ended June 30, 2026
Premiums $ 81,099 $ — $ 1,612 $ 1,612 $ — $ (408) $ 82,303
Product revenue — 12,489 — 12,489 — — 12,489
Service fees 4,111 7 410 417 — — 4,528
Operating revenue -
unaffiliated 85,210 12,496 2,022 14,518 — (408) 99,320
Operating revenue - affiliated — 9,354 13,318 22,672 10 (22,682) —
Operating revenue - total $ 85,210 $ 21,850 $ 15,340 $ 37,190 $ 10 $ (23,090) $ 99,320
Benefit expense $ 72,192 $ — $ 12,829 $ 12,829 $ 15 $ (12,397) $ 72,639
Cost of products sold — 20,303 — 20,303 — (9,348) 10,955
Operating expense 9,965 383 1,675 2,058 1,199 (1,345) 11,877
Operating gain (loss) $ 3,053 $ 1,164 $ 836 $ 2,000 $ (1,204) $ — $ 3,849
Six Months Ended June 30, 2025
Premiums $ 79,298 $ — $ 3,363 $ 3,363 $ — $ (503) $ 82,158
Product revenue — 11,851 — 11,851 — — 11,851
Service fees 3,715 7 455 462 — — 4,177
Operating revenue -
unaffiliated 83,013 11,858 3,818 15,676 — (503) 98,186
Operating revenue - affiliated — 8,901 10,159 19,060 397 (19,457) —
Operating revenue - total $ 83,013 $ 20,759 $ 13,977 $ 34,736 $ 397 $ (19,960) $ 98,186
Benefit expense $ 69,880 $ — $ 11,609 $ 11,609 $ 18 $ (9,489) $ 72,018
Cost of products sold — 19,168 — 19,168 — (8,892) 10,276
Operating expense 9,356 453 1,477 1,930 590 (1,579) 10,297
Operating gain (loss) $ 3,777 $ 1,138 $ 891 $ 2,029 $ (211) $ — $ 5,595
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated
statements of income for the three and six months ended June 30, 2026 and 2025 is as follows:
Three Months Ended
June 30 Six Months Ended
June 30
2026 2025 2026 2025
Reportable segments’ operating revenue $ 49,826 $ 49,421 $ 99,320 $ 98,186
Net investment income 704 486 1,469 1,076
Net losses on financial instruments (56) (131) (134) (595)
Total revenues $ 50,474 $ 49,776 $ 100,655 $ 98,667
-33-

-- 34 of 57 --

A reconciliation of reportable segments' operating gain to income before income tax expense included in our
consolidated statements of income for the three and six months ended June 30, 2026 and 2025 is as follows:
Three Months Ended
June 30 Six Months Ended
June 30
2026 2025 2026 2025
Income before income tax expense $ 1,937 $ 2,292 $ 4,241 $ 5,089
Net investment income (704) (486) (1,469) (1,076)
Net losses on financial instruments 56 131 134 595
Interest expense 364 341 721 685
Amortization of other intangible assets 110 147 222 302
Reportable segments’ operating gain $ 1,763 $ 2,425 $ 3,849 $ 5,595
-34-

-- 35 of 57 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be
read in conjunction with the accompanying consolidated financial statements and notes, as well as our consolidated financial
statements and notes as of and for the year ended December 31, 2025 and the MD&A included in our 2025 Annual Report on
Form 10-K. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this MD&A refer to Elevance
Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References
to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the three and six months ended
June 30, 2026 are not necessarily indicative of the results and trends that may be expected for the full year ending
December 31, 2026, or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving approximately 44.9 million medical members
through our affiliated health plans as of June 30, 2026. We are an independent licensee of the Blue Cross and Blue Shield
Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross
licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia,
Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in
the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of
Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem
Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees, as well as other
strategic partners. In addition, we serve members in numerous states as Wellpoint, Carelon, MMM and/or Simply Healthcare.
We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our
subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other
healthcare related services as Carelon Services.
Our portfolio consists of the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our Anthem-branded and affiliated Blue
Cross and/or Blue Shield licensed Medicare, Medicaid, and commercial Health Benefit plans;
• Wellpoint — represents our Wellpoint branded Medicare, Medicaid and commercial Health Benefit plans and other
non-BCBSA brands; and
• Carelon — represents our healthcare related services and capabilities, including our CarelonRx and Carelon Services
businesses.
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon
Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating
segment, as well as corporate expenses not allocated to our other reportable segments). For additional information, see Note
13, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly
Report on Form 10-Q.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2025 Annual Report on Form 10-
K.
-35-

-- 36 of 57 --

Business Trends
Medical Cost Trends: Our medical cost trends are primarily driven by changes in the utilization of services across all
provider types and the unit cost of these services. We work to mitigate these trends through various medical management
programs such as care and condition management, program integrity and specialty pharmacy management and utilization
management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from
our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health
status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new
high-cost prescription drugs, including increased utilization of specialty pharmaceuticals, new indications of existing
prescription drugs, provider contracting inflation, labor costs and healthcare fraud, waste and abuse.
Membership shifts from Medicaid into our Individual ACA (as defined below) business following the redetermination
process that began in April 2023, together with lower membership effectuation rates, particularly in geographies with high
concentrations of highly subsidized members, have driven a market-wide increase in morbidity, resulting in elevated medical
cost trends. Medicaid cost trends remain elevated due to higher population acuity and increased utilization of services. In
response, we are working on program improvements in partnership with the states, strengthening care and provider network
management, optimizing our clinical strategy to improve effectiveness and enhancing payment integrity to manage costs.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends.
We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken
by existing competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in
whole or in part, upon annual funding from the federal government and/or applicable state governments. Product pricing
remains competitive. Pricing of the Medicare and Medicaid programs may not adequately reflect current underlying
healthcare cost trends given the timing lag between when pricing is established and the start of the applicable contract, which
could adversely affect our financial results.
If the approvals of any annual premium rate changes by contracted government agencies are delayed, we are required to
defer the recognition of any premium rate increases to the period in which the premium rates become final. The impact of this
deferral can be significant in the period in which the increased premium rates are first recognized depending on the
magnitude of the premium rate increase, the number of members to which it applies and the length of the delay between the
effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change
in premium rate becomes effective and the change in the rate is known, which may be prior to the period in which the
contract amendment affecting the rate is finalized.
Affordable Care Act: We continue to participate in the Individual state- or federally-facilitated marketplaces (the “Public
Exchange”) in nearly all of our Anthem Blue Cross and Anthem Blue Cross and Blue Shield service areas. In 2025, we
expanded our operations into select service areas in Florida through our Simply Healthcare brand, and Maryland and Texas
through our Wellpoint brand. In 2026, we expanded into Washington through our Wellpoint brand. Going forward, we expect
the Public Exchange to be influenced by policy and regulatory changes, particularly around federal subsidies, compliance
requirements, and market stability.
CarelonRx: CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the
country and to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes all
core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management,
pharmacy networks, rebate administration, a prescription drug database and member services, as well as infusion services and
injectable therapies.
CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS
Health Corporation (“CVS”), pursuant to an agreement (the “CVS Agreement”) with the current contractual term extending
through December 31, 2027. We can elect to have CVS continue to provide services to us for a three-year extension period
on the same terms and conditions as in the current CVS Agreement in the event of a termination or non-renewal by either
party.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2025 Annual Report
on Form 10-K.
-36-

-- 37 of 57 --

Regulatory Trends and Uncertainties
The federal budget reconciliation legislation, known as the One Big Beautiful Bill Act (the “OBBBA”) was signed into
law on July 4, 2025. The OBBBA includes provisions that could impact our business and operations including: requiring
more frequent Medicaid reverifications for beneficiaries receiving coverage under a state’s Medicaid expansion program
implemented pursuant to the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation
Act of 2010, as amended (collectively, the “ACA”); and imposing work or community engagement requirements on certain
adults in the ACA Medicaid expansion population. The OBBBA also makes changes to federal requirements regarding
Medicaid state directed payments and provider taxes, including taxes on managed care organizations; delays implementation
of Medicaid final regulations on certain eligibility and enrollment provisions; reduces the allowable home equity asset
threshold for individuals seeking eligibility for long-term care under Medicaid; establishes a new Rural Health
Transformation program; eliminates the repayment limit for excess advanced Premium Tax Credits (“PTCs”) under the ACA;
modifies the rules regarding Health Savings Account (“HSA”) eligible plans under the ACA; and makes permanent an
extension of the safe harbor first established under the Coronavirus Aid, Relief, and Economic Security Act, allowing pre-
deductible coverage of telehealth services for HSA eligible high-deductible health plans; among other provisions.
Additional federal and state guidance is being issued to implement these OBBBA provisions. Implementation dates vary,
with many provisions impacting commercial plans effective January 1, 2026, and many Medicaid-related provisions effective
in 2027 and 2028. States may choose to implement certain Medicaid provisions as early as 2026.
In May 2026, the U.S. Department of Health and Human Services, Labor, and the Treasury (collectively, the “Tri-
Agencies”) issued final regulations updating the federal Independent Dispute Resolution (“IDR”) process used to determine
compensation to be paid by health plans to out-of-network providers in certain scenarios under the No Surprises Act. The
regulations are primarily procedural in nature and address the operations and administration of the IDR process. Additional
regulatory guidance or rulemakings are possible, and changes resulting from any such guidance or rulemakings, as well as
current and potential litigation, arbitration proceedings, and government audits related to the IDR and No Surprises Act,
could have an adverse effect on our business, cash flows, results of operations and financial condition.
In February 2026, Congress passed the Consolidated Appropriations Act of 2026, which includes pharmacy benefit
manager reforms requiring pharmacy benefit managers to remit all rebates, fees (other than bona fide service fees), and other
remuneration received from entities such as manufacturers and group purchasing organizations to commercial plan sponsors,
and to provide detailed commercial claims reporting, effective 30 months after enactment. The legislation also imposes
extensive reporting requirements and delinks pharmacy benefit manager compensation in Medicare Part D by prohibiting
pharmacy benefit managers from receiving remuneration related to Part D drugs in any form other than bona fide service fees
that cannot be based on a drug’s price, effective in 2028. There continues to be the potential that similar or additional
legislation may be adopted at the state or federal level.
In addition, in June 2025, the Centers for Medicare and Medicaid Services (“CMS”) finalized the Marketplace Integrity
and Affordability Regulation, which modifies the Public Exchange open enrollment period beginning in plan year 2027 and
eligibility for PTCs, among other requirements. In September 2025, a federal court delayed the effective dates for several
provisions of the Marketplace Integrity and Affordability Regulation pending the resolution of ongoing litigation challenging
the legality of those provisions. Also, in September 2025, CMS issued guidance modifying eligibility requirements for ACA
catastrophic plans.
In September 2024, the Tri-Agencies issued final regulations related to mental health parity that will require health plans
to make administrative and operational changes to comply with these final regulations. While some provisions became
effective on January 1, 2025, additional guidance from the Tri-Agencies is necessary to assess the full impact of these
regulations on our operations and financial results. Litigation has been filed challenging the final regulations.
-37-

-- 38 of 57 --

The Consolidated Appropriations Act of 2023 separated Medicaid eligibility redeterminations from the COVID-19
Public Health Emergency initially declared in January 2020. As a result, states were permitted to begin removing ineligible
beneficiaries from their Medicaid programs starting April 1, 2023, and the majority of our Medicaid markets began doing so
as of June 30, 2023. CMS required states to complete Medicaid eligibility redeterminations by December 31, 2025. Although
the federally mandated Medicaid eligibility redetermination period has ended, states continue to conduct regular eligibility
reverifications and the effects on Medicaid enrollment, member acuity, utilization and state rate-setting, as well as changes
arising from the OBBBA, may continue to affect our business.
In addition, subsequent budget reconciliation legislation enacted during 2023 through 2025 included provisions affecting
Medicaid eligibility enrollment and program financing, which may influence state Medicaid policies and beneficiary
coverage dynamics over time.
The Inflation Reduction Act of 2022 (“IRA”) includes several provisions that have impacted, and continue to impact, our
business. These provisions include extending the American Rescue Plan Act of 2021’s enhanced Advance Premium Tax
Credits (“APTCs”) through 2025; imposing a new corporate alternative minimum tax; establishing a one percent excise tax
on repurchases of stock by issuers; authorizing CMS to negotiate prices on a limited set of Medicare prescription drugs
beginning in 2026; instituting caps on insulin cost sharing in Medicare; redesigning the Medicare Part D benefit; requiring
drug manufacturers to pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump
Administration Medicare drug rebate rule until at least 2032. From 2021 to 2025, Individual market enrollment grew
significantly, driven in part by APTCs, which reduced Public Exchange coverage premiums for individuals who qualified.
This, in combination with lower membership effectuation rates, particularly in geographies with high concentrations of
highly subsidized members, have driven a market-wide increase in morbidity, resulting in elevated medical cost trends. The
APTCs expired on December 31, 2025. As a result, the cost of Public Exchange coverage premiums has increased for those
individuals previously receiving the APTCs, which has impacted our Individual market enrollment.
The ACA continues to impact our business and results of operations, including pricing, minimum medical loss ratios,
and the geographies in which our products are available.
We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving
methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data
submitted under the risk adjustment programs in ways that could increase financial recoveries from plans. For example, in
May 2025, CMS announced plans to substantially increase the scale and pace of Risk Adjustment Data Validation (“RADV”)
audits of Medicare Advantage plans. CMS has initiated these RADV audit changes, and the outcome could adversely affect
our financial condition and results of operations.
For additional discussion regarding regulatory trends and uncertainties, and risk factors that could cause actual results to
differ materially from those contained in forward-looking statements, see Part I, Item 1, “Business – Regulation,” Part I, Item
1A, “Risk Factors” and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” included in our 2025 Annual Report on Form 10-K.
Other Significant Items
Business and Operational Matters
In the first quarter of 2026, based on a strategic review of our operations, assets and investments, management initiated
the 2026 - 2027 Operating Model Transformation Program (the “Transformation Program”) to streamline decision-making,
simplify organizational structures, and enhance the use of advanced technologies, including artificial intelligence, across the
enterprise. The Transformation Program includes initiatives to reduce organizational layers, realign roles and responsibilities,
and design workflows to support more efficient, technology-enabled operations. These actions also include the modernization
of certain information technology platforms, targeted workforce reductions and role realignments. Actions to be taken under
the Transformation Program were ongoing as of June 30, 2026.
-38-

-- 39 of 57 --

Pursuant to CMS’ Medicare Advantage Star Ratings system, CMS annually awards between 1.0 and 5.0 Stars to
Medicare Advantage plans based on performance in several categories. Plans must have a Star Rating of 4.0 or higher to
qualify for bonus payments. Our 2025 Star Ratings, which are used for payment year 2026, reflect that approximately 40% of
our Medicare Advantage members were enrolled in plans rated at least 4.0 Stars or higher. CMS released our 2026 Star
Ratings in October 2025, which will be used to determine our Medicare Advantage bonus payments in 2027. Our 2026 Star
Ratings reflect that approximately 59% of our Medicare Advantage members are enrolled in plans rated at least 4.0 Stars or
higher, or the equivalent.
CMS Notice
In connection with the notice that the Company received in February 2026 from CMS regarding certain Medicare
Advantage risk adjustment data submission requirements related to diagnosis codes for dates of service 2015 through April
2023, CMS provided a series of steps required to be completed by July 31, 2026 in order to avoid sanctions being imposed on
the Company. On July 13, 2026, the Company received a letter from CMS stating that the Company has completed all
required steps, sanctions will not be imposed and the enforcement process for this matter has been closed.
Litigation Matters
We have been a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or
Blue Shield licensees (the “Blue plans”) across the country. These cases have been consolidated into a single, multi-district
proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”) that is pending before the U.S.
District Court for the Northern District of Alabama (the “Court”). Generally, the lawsuits in the BCBSA Litigation challenge
elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans along with
other arrangements in violation of the Sherman Antitrust Act and related state laws. The cases were brought by two
nationwide classes of plaintiffs, health plan subscribers and providers.
The BCBSA and Blue plans approved and entered into a settlement agreement and release with the subscriber plaintiffs
(the “Subscriber Settlement Agreement”) and a separate settlement agreement and release with the provider plaintiffs (the
“Provider Settlement Agreement”), which settlement agreements received final approval from the Court in September 2022
and August 2025, respectively.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed.
Additionally, follow-on cases involving the entities that opted out of the Provider Settlement Agreement have been filed and
centralized in the BCBSA Litigation multi-district proceeding.
For additional information regarding the BCBSA Litigation, see Note 10, “Commitments and Contingencies – Litigation
and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Selected Operating Performance
From June 30, 2025 to June 30, 2026, total medical membership declined by 1.5%. This was driven by attrition in
Medicaid membership, primarily as a result of eligibility redeterminations, and decreases in our Medicare Advantage,
Employer Group Risk-Based and FEP® businesses. These decreases were partially offset by increases in our Employer Group
Fee-Based business.
Operating revenue for the three months ended June 30, 2026 was $49,826, an increase of $405, or 0.8%, from the three
months ended June 30, 2025. Operating revenue for the six months ended June 30, 2026 was $99,320, an increase of $1,134,
or 1.2%, from the six months ended June 30, 2025. The increases for the three and six months ended June 30, 2026 were
primarily the result of premium rate increases in our Health Benefits segment in recognition of medical cost trends and
growth in CarelonRx product revenues, partially offset by membership attrition.
Shareholders’ net income for the three months ended June 30, 2026 was $1,463, a decrease of $280, or 16.1%, from the
three months ended June 30, 2025. Shareholders’ net income for the six months ended June 30, 2026 was $3,227, a decrease
of $699, or 17.8%, from the six months ended June 30, 2025. The decrease in net income for the three months ended June 30,
2025 was primarily due to a decrease in operating gain in our Corporate and Other, Health Benefits and Carelon Services
-39-

-- 40 of 57 --

segments. The decrease was partially offset by increased net investment income, decreased net losses on financial instruments
and decreased income tax expense. The decrease in net income for the six months ended June 30, 2026 was primarily due to
the loss contingency accrual for our best estimate of the identified potential exposure for the resubmission of certain historical
Medicare Advantage risk adjustment data within our Corporate & Other segment and a decrease in operating gain in our
Health Benefits and Carelon Services segments. The decrease was partially offset by decreased net losses on financial
instruments, increased net investment income and decreased income tax expense.
Our fully-diluted shareholders’ earnings per share (“EPS”) was $6.71 for the three months ended June 30, 2026, which
represented a 13.1% decrease from EPS of $7.72 for the three months ended June 30, 2025. Our EPS was $14.73 for the six
months ended June 30, 2026, which represented a 15.0% decrease from EPS of $17.33 for the six months ended June 30,
2025. The decreases in EPS for both periods resulted primarily from decreased shareholders' net income, partially offset by
the impact of fewer diluted shares outstanding.
Operating cash flow for the six months ended June 30, 2026 and 2025 was $6,245 and $3,071, respectively. The increase
in net cash provided by operating activities was primarily due to favorable working capital impacts, partially offset by lower
shareholders’ net income for the six months ended June 30, 2026.
Membership and Other Metrics
The following table presents our medical membership by customer type as of June 30, 2026 and 2025. Also included
below is other membership by product and other metrics. The membership data and other metrics presented are unaudited and
in certain instances include estimates of the number of members represented by each contract at the end of the period. The
CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of days a prescription
covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services Consumers
Served metric represents the number of consumers receiving one or more healthcare-related services from Carelon Services
who are members of our affiliated health plans as well as those who are members of non-affiliated health plans. For a more
detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” included in our 2025 Annual Report on Form 10-K.
-40-

-- 41 of 57 --

June 30
2026 2025 Change % Change
Medical Membership (in thousands)
Individual 1,317 1,348 (31) (2.3) %
Employer Group Risk-Based 3,417 3,615 (198) (5.5) %
Commercial Risk-Based 4,734 4,963 (229) (4.6) %
BlueCard® 6,582 6,570 12 0.2 %
Employer Group Fee-Based 20,931 20,584 347 1.7 %
Commercial Fee-Based 27,513 27,154 359 1.3 %
Medicare Advantage 1,897 2,255 (358) (15.9) %
Medicare Supplement 893 874 19 2.2 %
Total Medicare 2,790 3,129 (339) (10.8) %
Medicaid 8,358 8,733 (375) (4.3) %
Federal Employee Program® 1,554 1,642 (88) (5.4) %
Total Medical Membership 44,949 45,621 (672) (1.5) %
Other Membership (in thousands)
Dental Members 7,480 7,346 134 1.8 %
Dental Administration Members 1,940 1,961 (21) (1.1) %
Vision Members 11,912 10,770 1,142 10.6 %
Medicare Part D Standalone Members 78 219 (141) (64.4) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts 80.9 83.3 (2.4) (2.9) %
Carelon Services Consumers Served 92.4 97.3 (4.9) (5.0) %
Medical Membership
The decrease in medical membership was primarily driven by attrition in Medicaid membership, primarily as a result of
eligibility redeterminations, and decreases in our Medicare Advantage, Employer Group Risk-Based and FEP® businesses.
These decreases were partially offset by increases in our Employer Group Fee-Based business.
Other Membership
Our other membership has the potential to be impacted by changes in our medical membership, as our medical members
often purchase our other products that are ancillary to our health business. Dental membership increased primarily due to
favorable sales in our Employer Group business. Dental Administration membership decreased primarily due to unfavorable
in-group change within other BCBSA plans. Vision membership increased primarily due to higher sales in our Medicaid,
Employer Group and Individual health plans, partially offset by lower sales in our Medicare business.
-41-

-- 42 of 57 --

Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three and six months ended
June 30, 2026 and 2025 are as follows:
Three Months
Ended
June 30
Six Months
Ended
June 30
Change
Three Months Ended
June 30 Six Months Ended
June 30
2026 vs. 2025 2026 vs. 2025
2026 2025 2026 2025 $ % $ %
Total operating revenue $ 49,826 $ 49,421 $ 99,320 $ 98,186 $ 405 0.8 % $ 1,134 1.2 %
Net investment income 704 486 1,469 1,076 218 44.9 % 393 36.5 %
Net losses on financial instruments (56) (131) (134) (595) 75 57.3 % 461 77.5 %
Total revenues 50,474 49,776 100,655 98,667 698 1.4 % 1,988 2.0 %
Benefit expense 37,024 36,706 72,639 72,018 318 0.9 % 621 0.9 %
Cost of products sold 5,492 5,293 10,955 10,276 199 3.8 % 679 6.6 %
Operating expense 5,547 4,997 11,877 10,297 550 11.0 % 1,580 15.3 %
Other expense1 474 488 943 987 (14) (2.9) % (44) (4.5) %
Total expenses 48,537 47,484 96,414 93,578 1,053 2.2 % 2,836 3.0 %
Income before income tax expense 1,937 2,292 4,241 5,089 (355) (15.5) % (848) (16.7) %
Income tax expense 483 548 1,027 1,161 (65) (11.9) % (134) (11.5) %
Net income 1,454 1,744 3,214 3,928 (290) (16.6) % (714) (18.2) %
Net loss (gain) attributable to noncontrolling interests 9 (1) 13 (2) 10 NM 15 NM
Shareholders’ net income $ 1,463 $ 1,743 $ 3,227 $ 3,926 $ (280) (16.1) % $ (699) (17.8) %
Average diluted shares outstanding 217.9 225.8 219.1 226.5 (7.9) (3.5) % (7.4) (3.3) %
Diluted shareholders’ earnings per share $ 6.71 $ 7.72 $ 14.73 $ 17.33 $ (1.01) (13.1) % $ (2.60) (15.0) %
Effective tax rate 24.9 % 23.9 % 24.2 % 22.8 % 100 bp3 140 bp3
Benefit expense ratio2 89.7 % 88.9 % 88.3 % 87.7 % 80 bp3 60 bp3
Operating expense ratio4 11.1 % 10.1 % 12.0 % 10.5 % 100 bp3 150 bp3
Income before income tax expense as a percentage of
total revenues 3.8 % 4.6 % 4.2 % 5.2 % (80) bp3 (100) bp3
Shareholders’ net income as a percentage of total
revenues 2.9 % 3.5 % 3.2 % 4.0 % (60) bp3 (80)bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense and amortization of other intangible assets.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended June 30, 2026 and 2025
were $41,279 and $41,271, respectively. Premiums for the six months ended June 30, 2026 and 2025 were $82,303 and $82,158, respectively.
3 bp = basis point; one hundred basis points = 1%.
4 Operating expense ratio represents operating expense as a percentage of total operating revenue.
Three Months Ended June 30, 2026 Compared to the Three Months Ended June 30, 2025
Total operating revenue increased primarily as a result of premium rate increases in our Health Benefits segment in
recognition of medical cost trends and growth in CarelonRx product revenues, partially offset by membership attrition.
Net investment income increased primarily due to higher income from alternative investments, partially offset by lower
income from fixed maturity securities.
Net losses on financial instruments decreased due to lower impairment on other invested assets and lower realized losses
on sales of financial instruments.
-42-

-- 43 of 57 --

Benefit expense increased primarily due to higher medical costs across most lines of business within our Health Benefits
segment. These increases were partially offset by decreases in Carelon Services benefit expense related to the partial
termination and modification of a care delivery services contract with an unaffiliated customer.
Our benefit expense ratio increased primarily as a result of expected elevated medical cost trend in our Medicaid and
Medicare businesses, partially offset by improved performance in our Individual ACA business.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy
customers. Cost of products sold increased as a result of a higher cost per prescription in 2026, reflecting pricing impacts and
product mix, despite lower adjusted prescription volumes.
Operating expense increased primarily due to increases in targeted investments to support and strengthen our workforce
and accelerate technology adoption, an increase in expenses to address regulatory matters and an increase in premium tax
expenses and assessments.
Our operating expense ratio increased primarily due to targeted investments to support and strengthen our workforce and
accelerate technology adoption, an increase in expenses to address regulatory matters and an increase in premium tax
expenses and assessments.
Other expense decreased primarily due to a decrease in amortization of other intangible assets due to assets being
amortized under an accelerated depreciation method, which results in higher expense recognition in earlier periods and
progressively lower amortization in later periods, partially offset by an increase in interest expense.
Our effective tax rate increased primarily due to the net increase in reserves for uncertain tax positions.
Our shareholders’ net income as a percentage of total revenues decreased in the three months ended June 30, 2026 as
compared to the three months ended June 30, 2025 as a result of all factors discussed above.
Six Months Ended June 30, 2026 Compared to the Six Months Ended June 30, 2025
Total operating revenue increased primarily as a result of premium rate increases in our Health Benefits segment in
recognition of medical cost trends and growth in CarelonRx product revenues, partially offset by membership attrition.
Net investment income increased primarily due to higher income from alternative investments, partially offset by lower
income from fixed maturity securities.
Net losses on financial instruments decreased due to lower impairment on other invested assets and lower realized losses
on sales of financial instruments.
Benefit expense increased primarily due to higher medical costs across all lines of business within our Health Benefits
segment, with the exception of Medicare. These increases were partially offset by decreases in Carelon Services benefit
expense related to the partial termination and modification of a care delivery services contract with an unaffiliated customer.
Our benefit expense ratio increased primarily due to expected elevated medical cost trend in our Medicaid business,
partially offset by improved performance in our Individual ACA business.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy
customers. Cost of products sold increased as a result of a higher cost per prescription in 2026, reflecting pricing impacts and
product mix, despite lower adjusted prescription volumes.
Operating expense increased primarily due to the loss contingency accrual for our best estimate of the identified potential
exposure for the resubmission of certain historical Medicare Advantage risk adjustment data, increases in targeted
investments to support and strengthen our workforce and accelerate technology adoption and increases related to the
Transformation Program.
Our operating expense ratio increased primarily due to the loss contingency accrual for our best estimate of the identified
potential exposure for the resubmission of certain historical Medicare Advantage risk adjustment data, increases in targeted
-43-

-- 44 of 57 --

investments to support and strengthen our workforce and accelerate technology adoption and increases related to the
Transformation Program.
Other expense decreased primarily due to a decrease in amortization of other intangible assets due to assets being
amortized under an accelerated depreciation method, which results in higher expense recognition in earlier periods and
progressively lower amortization in later periods, partially offset by an increase in interest expense.
Our effective tax rate increased primarily due to the net increase in reserves for uncertain tax positions.
Our shareholders’ net income as a percentage of total revenues decreased in the six months ended June 30, 2026 as
compared to six months ended June 30, 2025 as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted
accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in
understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as
premium income, product revenue and service fees. Operating gain is calculated as total operating revenue less benefit
expense, cost of products sold and operating expense. It does not include net investment income, net losses on financial
instruments, loss/gain on sale of business, interest expense, amortization of other intangible assets or income taxes, as these
items are managed in our corporate shared service environment and are not the responsibility of operating segment
management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a
basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive
compensation targets. This information is not intended to be considered in isolation or as a substitute for income before
income tax expense, shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to
similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the
amounts of total revenue included in the consolidated statements of income and a reconciliation of income before income tax
expense to reportable segments’ operating gain, see Note 13, “Segment Information,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon
Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating
segment, as well as corporate expenses not allocated to our other reportable segments). For additional information, see Note
13, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly
Report on Form 10-Q.
-44-

-- 45 of 57 --

The following table presents a summary of the reportable segment financial information for the three and six months
ended June 30, 2026 and 2025:
Six Months Ended
June 30
Three Months
Ended
June 30
Three Months
Ended
June 30 Six Months Ended
June 30
2026 vs. 2025
Change 2026 vs. 2025
Change
2026 2025 2026 2025 $ % $ %
Operating Revenue
Health Benefits $ 42,720 $ 41,582 $ 85,210 $ 83,013 $ 1,138 2.7 % $ 2,197 2.6 %
CarelonRx 11,250 10,643 21,850 20,759 607 5.7 % 1,091 5.3 %
Carelon Services 7,975 7,441 15,340 13,977 534 7.2 % 1,363 9.8 %
Corporate & Other 6 232 10 397 (226) (97.4) % (387) (97.5) %
Eliminations (12,125) (10,477) (23,090) (19,960) (1,648) 15.7 % (3,130) 15.7 %
Total operating revenue $ 49,826 $ 49,421 $ 99,320 $ 98,186 $ 405 0.8 % $ 1,134 1.2 %
Operating Gain (Loss)
Health Benefits $ 896 $ 1,560 $ 3,053 $ 3,777 $ (664) (42.6) % $ (724) (19.2) %
CarelonRx 582 536 1,164 1,138 46 8.6 % 26 2.3 %
Carelon Services 366 400 836 891 (34) (8.5) % (55) (6.2) %
Corporate & Other (81) (71) (1,204) (211) (10) 14.1 % (993) 470.6 %
Total operating gain $ 1,763 $ 2,425 $ 3,849 $ 5,595 $ (662) (27.3) % $ (1,746) (31.2) %
Operating Margin
Health Benefits 2.1 % 3.8 % 3.6 % 4.5 % (170) bp (90) bp
CarelonRx 5.2 % 5.0 % 5.3 % 5.5 % 20 bp (20) bp
Carelon Services 4.6 % 5.4 % 5.4 % 6.4 % (80) bp (100) bp
Total operating margin 3.5 % 4.9 % 3.9 % 5.7 % (140) bp (180) bp
bp = basis point; one hundred basis points = 1%.
The following table summarizes the operating revenues for our Commercial, Medicare, Medicaid and FEP® lines of
business within our Health Benefits segment for the three and six months ended June 30, 2026 and 2025:
Three Months
Ended
June 30 Six Months Ended
June 30
Three Months
Ended
June 30 Six Months Ended
June 30
2026 vs. 2025
Change 2026 vs. 2025
Change
2026 2025 2026 2025 $ % $ %
Health Benefits Operating Revenue
Commercial 1 $ 13,561 $ 12,453 $ 26,799 $ 24,805 $ 1,108 8.9 % $ 1,994 8.0 %
Medicare 10,962 11,446 21,953 22,852 (484) (4.2) % (899) (3.9) %
Medicaid 14,444 13,911 28,724 27,954 533 3.8 % 770 2.8 %
FEP® 3,753 3,772 7,734 7,402 (19) (0.5) % 332 4.5 %
Total Health Benefits operating revenue $ 42,720 $ 41,582 $ 85,210 $ 83,013 $ 1,138 2.7 % $ 2,197 2.6 %
1 Operating revenue within our Commercial line of business related to our Individual ACA plans was $2,720 and $2,328 for the three months ended June 30,
2026 and 2025, respectively. Operating revenue within our Commercial line of business related to our Individual ACA plans was $5,260 and $4,689
for the six months ended June 30, 2026 and 2025, respectively.
-45-

-- 46 of 57 --

Three Months Ended June 30, 2026 Compared to the Three Months Ended June 30, 2025
Health Benefits
Operating revenue increased primarily as a result of higher premium yields driven by premium increases in all of our
lines of business, partially offset by deliberate repositioning in our Medicare Advantage business and Medicaid membership
attrition.
Operating gain decreased primarily as a result of higher overall medical costs and increases in targeted investments to
support and strengthen our workforce and accelerate technology adoption, partially offset by higher operating revenue.
CarelonRx
Operating revenue increased primarily due to higher average revenue per prescription, partially offset by a negative
change in product mix and lower prescription volumes.
Operating gain increased primarily due to improved specialty pharmacy profitability.
Carelon Services
Operating revenue increased primarily due to the continued expansion of risk-based capabilities in our specialty care
solutions and behavioral health services. These increases were partially offset by decreases related to the partial termination
and modification of a care delivery services contract with an unaffiliated customer and fewer post-acute solutions services
provided as a result of lower Medicare membership.
The decrease in operating gain was primarily driven by less favorable results on certain contracts and lower health plan
membership within our post-acute solutions services, partially offset by improved performance in Carelon Insights.
Corporate & Other
Operating revenue decreased primarily due to lower affiliate revenues.
Operating loss increased primarily due to an increase in unallocated corporate expenses.
Six Months Ended June 30, 2026 Compared to the Six Months Ended June 30, 2025
Health Benefits
Operating revenue increased primarily as a result of higher premium yields driven by premium increases in all of our
lines of business, partially offset by deliberate repositioning in our Medicare Advantage business and Medicaid membership
attrition.
Operating gain decreased primarily due to higher overall medical costs and increases in targeted investments to support
and strengthen our workforce and accelerate technology adoption, partially offset by higher operating revenue.
CarelonRx
Operating revenue increased primarily due to higher average revenue per prescription, partially offset by a negative
change in product mix and lower prescription volumes.
The increase in operating gain was primarily driven by improved specialty pharmacy profitability and lower operating
expenses, partially offset by normal timing variations in recognition of performance-related adjustments.
Carelon Services
Operating revenue increased primarily due to the continued expansion of risk-based capabilities in our specialty care
solutions and behavioral health services. These increases were partially offset by decreases related to the partial termination
and modification of a care delivery services contract with an unaffiliated customer and fewer post-acute solutions services
provided as a result of lower Medicare membership.
-46-

-- 47 of 57 --

The decrease in operating gain was primarily driven by less favorable results on certain contracts and lower health plan
membership within our post acute solutions services, lower health plan membership and seasonality related to the launch of
risk-based capabilities in our specialty care solutions business. The decrease was partially offset by improved performance in
our behavioral health business and the expansion of CareBridge.
Corporate & Other
Operating revenue decreased primarily due to lower affiliate revenues.
Operating loss increased primarily due to increased unallocated corporate expenses, primarily associated with the loss
contingency accrual for our best estimate of the identified potential exposure for the resubmission of certain historical
Medicare Advantage risk adjustment data and the Transformation Program.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management
to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and
accompanying notes and within this MD&A. We consider our most important accounting policies that require significant
estimates and management judgment to be those policies with respect to liabilities for medical claims payable, goodwill and
other intangible assets and investments. Our accounting policies related to these items are discussed in our 2025 Annual
Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated
financial statements as of and for the year ended December 31, 2025, as well as in the “Critical Accounting Policies and
Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of
Operations.” As of June 30, 2026, our critical accounting policies and estimates have not changed from those described in our
2025 Annual Report on Form 10-K.
We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In
general, our estimates are based on historical experience, evaluation of current trends, information from third-party
professionals and various other assumptions that we believe to be reasonable under the known facts and circumstances.
Estimates can require a significant amount of judgment, and a different set of assumptions could result in material changes to
our reported results.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims
payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of June 30,
2026, our critical accounting policies and estimates related to medical claims payable have not changed from those described
in our 2025 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims
payable for the six months ended June 30, 2026 and 2025, see Note 8, “Medical Claims Payable,” of the Notes to
Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred
but not paid liability estimates for the six months ended June 30, 2026 and 2025, which are the trend and completion factors.
These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider
reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim
submission patterns and operational changes resulting from business combinations.
Favorable Developments by
Changes in Key Assumptions
Six Months Ended
June 30
2026 2025
Assumed trend factors $ 636 $ 1,013
Assumed completion factors 559 52
Total $ 1,195 $ 1,065
-47-

-- 48 of 57 --

The favorable development recognized in the six months ended June 30, 2026 resulted from trend factors in late 2025
developing more favorably than originally expected as well as from faster than expected development of completion factors
from the latter part of 2025. The favorable development recognized in the six months ended June 30, 2025 resulted from
trend factors in late 2024 developing more favorably than originally expected as well as a smaller contribution from faster
than expected development of completion factors from the latter part of 2024.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 78.9% and
80.3% for the six months ended June 30, 2026 and 2025, respectively. This ratio serves as an indicator of claims processing
speed whereby speed for claims payments was slightly slower during the six months ended June 30, 2026 as compared to the
six months ended June 30, 2025.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims
payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For
the six months ended June 30, 2026, this metric was 7.7%, which was mainly driven by both favorable trend factor
development at the end of 2025 as well as favorable completion factor development from 2025. For the six months ended
June 30, 2025, this metric was 7.3%, mainly driven by favorable trend factor development at the end of 2024, with favorable
completion factor development from 2024 also contributing.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred
medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net
incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred
medical claims and the consistency in our methodology. For the six months ended June 30, 2026, this metric was 0.8%,
which was calculated using the redundancy of $1,195. For the six months ended June 30, 2025, the comparable metric was
0.9%, which was calculated using the redundancy of $1,065. We believe these metrics demonstrate an appropriate and
consistent level of reserve conservatism.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the
sale or maturity of our investment securities, proceeds from borrowings and proceeds from the issuance of common stock
under our employee stock plans. Cash disbursements result mainly from claims payments, operating expenses, taxes,
purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases
of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and
timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on
our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included
in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” included in our 2025 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three and six months ended June 30,
2026, see Note 4, “Investments,” Note 5, “Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock –
Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in
Part I, Item 1 of this Quarterly Report on Form 10-Q.
-48-

-- 49 of 57 --

Liquidity
A summary of our major sources and uses of cash and cash equivalents for the six months ended June 30, 2026 and 2025
is as follows:
Six Months Ended
June 30
2026 2025 Change
Sources of Cash:
Net cash provided by operating activities $ 6,245 $ 3,071 $ 3,174
Purchases of subsidiaries, net of cash acquired 5 — 5
Proceeds from sales, maturities, calls and redemptions of investments, net of
purchases — 329 (329)
Proceeds from issuance of common stock under employee stock plans 63 21 42
Changes in bank overdrafts — 631 (631)
Total sources of cash 6,313 4,052 2,261
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and
redemptions (813) — (813)
Repurchase and retirement of common stock (1,358) (1,258) (100)
Purchases of property and equipment (522) (463) (59)
Repayments of short- and long-term debt, net of issuances (900) (1,255) 355
Cash dividends (749) (771) 22
Changes in bank overdrafts (1,181) — (1,181)
Other uses of cash, net (37) (35) (2)
Total uses of cash (5,560) (3,782) (1,778)
Effect of foreign exchange rates on cash and cash equivalents (12) 2 (14)
Net increase (decrease) in cash and cash equivalents $ 741 $ 272 $ 469
The increase in net cash provided by operating activities was primarily due to favorable working capital impacts,
partially offset by lower shareholders’ net income for the six months ended June 30, 2026.
Other significant changes in cash year-over-year included (a) decreased usage of cash to repay short-and long-term debt,
net of issuances, and (b) increased cash outflow from changes in bank overdrafts, increased purchases of investments, net of
proceeds from sales, maturities, calls and redemptions and increased repurchases and retirements of common stock.
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and
investments in fixed maturity and equity securities of $38,773 at June 30, 2026. Since December 31, 2025, total cash, cash
equivalents and investments in fixed maturity and equity securities increased by $1,537, primarily due to increased cash
generated from operations and decreased cash used in repayment of short- and long-term debt, net of issuances. This increase
was partially offset by increased cash used for changes in bank overdrafts and increased amounts for the repurchase and
retirement of common stock.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends
and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by
insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory
accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our
subsidiaries.
At June 30, 2026, we held $2,062 of cash, cash equivalents and investments at the parent company, which are available
for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases
and dividends to shareholders, repurchases of debt securities and debt and interest payments.
-49-

-- 50 of 57 --

Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to
refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us
to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the
occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 9, “Debt,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our
consolidated balance sheets included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Our debt-to-capital ratio is
calculated as total debt divided by total debt plus total equity. Total debt is the sum of short-term borrowings, current portion
of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating
agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a
maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to
similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 40.8% and 42.1% as of
June 30, 2026 and December 31, 2025, respectively.
Our senior debt is rated “A-” by S&P Global Ratings, “BBB+” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor
Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our
credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely
impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited
amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and
securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for
general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our
subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides credit of up to $5,000 and matures in September 2030. Our ability to borrow under the 5-Year
Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-
capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year
Facility. As of June 30, 2026, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 40.8%. We
do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating
flexibility. As of June 30, 2026, we were in compliance with all of our debt covenants under the 5-Year Facility.
We have an authorized commercial paper program of up to $5,000, the proceeds of which may be used for general
corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash
on hand and/or our 5-Year Facility to redeem any outstanding commercial paper upon maturity. We had $0 and $0 of
outstanding commercial paper at June 30, 2026 and December 31, 2025, respectively.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively,
the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. We had $0 and $150 of outstanding short-term borrowings from the FHLBs as of June 30, 2026 and
December 31, 2025, respectively.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at June 30, 2026, see Note 4, “Investments,” Note 5,
“Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock – Use of Capital – Dividends and Stock
-50-

-- 51 of 57 --

Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report
on Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile
have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance
organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital for
Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital
adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the
formula for calculating the RBC requirements, which are designed to take into account asset, insurance, interest rate and
other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an
insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as
appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2025,
which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC
requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital
requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California
subsidiaries. For additional information, see Note 21, “Statutory Information,” in our audited consolidated financial
statements as of and for the year ended December 31, 2025 included in Part II, Item 8 of our 2025 Annual Report on Form
10-K.
Future Sources and Uses of Liquidity
We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial
paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash
disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in Part II, Item 7 of our 2025
Annual Report on Form 10-K. For additional updates regarding our estimated long-term liquidity requirements, see Note 5,
“Derivative Financial Instruments,” Note 9, “Debt,” and the “Other Contingencies” and “Contractual Obligations and
Commitments” sections of Note 10, “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements
included in Part I, Item 1 of this Quarterly Report on Form 10-Q. We believe that funds from future operating cash flows,
cash and investments and funds available under our 5-Year Facility and/or from public or private financing sources will be
sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
-51-

-- 52 of 57 --

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are
generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan,” “potential,” “predict,” and similar expressions are intended to identify forward-
looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying
assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many
of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance
on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and
consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange
Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances
occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and
utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale
medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes
in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare,
insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of
cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or
regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize
our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as
intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market
conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures
and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and
uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex
regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid
Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein;
a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government
investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks
associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice
or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and
CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in
general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible
assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of
capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy
of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of
outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further
increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses
with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with
our international operations; and various laws and provisions in our governing documents that may prevent or discourage
takeovers and business combinations.
-52-

-- 53 of 57 --

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,”
included in our 2025 Annual Report on Form 10-K. There have been no material changes to any of these risks since
December 31, 2025.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation as of June 30, 2026, under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely
alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our
reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be
disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our
management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended
June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For information regarding legal proceedings at June 30, 2026, see the “Litigation and Regulatory Proceedings” and
“Other Contingencies” sections of Note 10, “Commitments and Contingencies” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which information is incorporated herein by
reference.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the
factors discussed in Part I, Item 1A, “Risk Factors” of our 2025 Annual Report on Form 10-K, which could materially affect
our business, financial condition or future results. The risks described in our 2025 Annual Report on Form 10-K are not the
only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial
also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in Part I, Item 1A of our 2025 Annual Report on
Form 10-K.
-53-

-- 54 of 57 --

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
April 1, 2026 to April 30, 2026 376,162 $ 306.81 374,414 $ 5,456
May 1, 2026 to May 31, 2026 211,481 385.63 209,105 5,375
June 1, 2026 to June 30, 2026 101,863 381.44 95,907 5,337
689,506 679,426
1 Total number of shares purchased includes 10,080 shares delivered to or withheld by us in connection with employee
payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock
issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these
shares purchased.
2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of
Directors, which the Board of Directors evaluates periodically. During the three months ended June 30, 2026, we
repurchased 679,426 shares at an aggregate cost of $234 under the program, including the cost of options to purchase
shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent
authorized increase to the program was $8,000 on October 15, 2024 by our Audit Committee, pursuant to authorization
granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we
reserve the right to discontinue the program at any time.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the
Securities Exchange Act of 1934, as amended) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or
“non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
-54-

-- 55 of 57 --

ITEM 6. EXHIBITS
Exhibit
Number Exhibit
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June
27, 2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on
June 28, 2022.
3.2 Bylaws of the Company, as amended effective October 4, 2023, incorporated by reference to Exhibit 3.1
to the Company’s Current Report on Form 8-K filed on October 5, 2023.
4.5 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of
any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange
Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange
Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS XBRL Instance Document - the instant document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
-55-

-- 56 of 57 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
ELEVANCE HEALTH, INC.
Registrant
July 15, 2026 By: /S/ MARK B. KAYE
Mark B. Kaye
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
July 15, 2026 By: /S/ RONALD W. PENCZEK
Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-56-

-- 57 of 57 --